# Medical Question & Answer

**Sample ID**: 136141cb-c301-4e49-9ce2-138336580eaf
**Dataset Index**: 2310

---

## Question

What is the dose of pyridoxin given for patient on INH patient WT is 41 KG

---

## Answer

> Let's see… What do we have here? The user is asking about the appropriate dose of pyridoxine (vitamin B6) for a 41 kg patient who is receiving isoniazid, with attention to the differences between prophylaxis and treatment of deficiency or overdose. Let's break this down step-by-step. First, I need to think about whether the indication is routine prophylaxis with isoniazid to prevent peripheral neuropathy. Then, I should verify adult dosing recommendations and how body weight factors in. Next, I will consider special populations such as pediatrics, pregnancy, malnutrition, and renal failure. After that, I should distinguish prophylaxis from treatment of established pyridoxine deficiency and from isoniazid overdose, because the dosing is entirely different. Finally, I will reconcile any discrepancies between sources and state a clear recommendation with safety monitoring advice.

> Let me first confirm the clinical scenario. For a 41 kg adult on isoniazid, the usual indication for pyridoxine is prophylaxis against INH-associated peripheral neuropathy. The INH dose in adults is commonly 300 mg daily, which exceeds the 5 mg/kg threshold in lighter adults and may raise neurotoxicity risk, making pyridoxine prudent even outside high-risk groups, particularly in populations with lower body weights or malnutrition [^115Et9Cm] [^114pRCGn].

> Now, I need to check adult prophylaxis dosing. Authoritative HIV OI guidelines consistently recommend pyridoxine 25–50 mg orally once daily with isoniazid for all adults to prevent neuropathy, without weight-based titration; the adult dose is fixed within that range, typically 25 mg or 50 mg daily depending on tolerance and risk profile [^116LLnYh] [^112nfNNG] [^114pC1Y7]. Wait, let me verify that there is truly no weight-based adult adjustment; yes, multiple high-credibility sources present a flat daily dose of 25–50 mg regardless of body weight, including in fixed-dose combinations and programmatic implementations, so weight does not alter the prophylactic adult dose [^114pC1Y7] [^111BtTjp].

> I should confirm the pharmacologic rationale and whether dose scaling with INH exposure changes practice. INH can cause functional pyridoxine deficiency by inhibiting pyridoxal phosphokinase and forming inactive complexes, thereby impairing GABA synthesis and predisposing to neuropathy; this mechanistic risk underpins universal adult prophylaxis at 25–50 mg/day rather than a weight-based regimen in standard-risk adults [^116uu81B] [^113bEwGn]. Hold on, let's not jump to conclusions about using a higher prophylactic dose just because the patient weighs less; current adult guidelines do not recommend exceeding 50 mg/day for prophylaxis absent special circumstances [^116LLnYh].

> But wait, what if the patient is in a higher-risk category or receiving higher INH exposures such as in the 3HP weekly regimen or high-dose INH for drug-resistant TB? In 3HP (weekly INH 900 mg), many experts and programs advise pyridoxine co-administration due to higher peak INH exposure, even though original RCTs did not universally mandate it; WHO and HIV OI guidance endorse pyridoxine 50 mg once weekly with 3HP, and many programs prefer daily 25–50 mg in lower-weight adults given observed systemic drug reactions and pharmacokinetic concerns, though the fixed 900 mg INH dose in 3HP already exceeds weight-based norms for smaller adults [^11442oyd] [^114m1E8g] [^111sT9Pn]. I should double-check that 3HP guidance indeed allows 50 mg weekly; yes, HIV OI guidance specifies 50 mg once weekly with 3HP, but many clinicians individualize toward daily pyridoxine in underweight adults to mitigate neurotoxicity risk [^11442oyd] [^114pC1Y7].

> Next, I should review special populations where pediatric-style weight-based dosing applies. In children, exclusively breastfed infants, those with nutritional deficiencies, and all children with HIV, pyridoxine 1–2 mg/kg/day is recommended, with a hard maximum of 25–50 mg/day. Pregnancy and lactation similarly warrant prophylaxis, and many programs use 50 mg/day during pregnancy because maternal and fetal neurotoxicity risk is increased with INH [^112Q8xQ1] [^112BKCQG] [^113wi88x] [^117JSaF8]. Hold on, I should verify that adult fixed dosing does not apply to adolescents with low weight; correct, the pediatric weight-based maximum still applies when using the 1–2 mg/kg/day schema in adolescents at risk, capping at 50 mg/day [^112Q8xQ1].

> I will now examine the approach when pyridoxine deficiency is already established. If INH has already caused symptomatic neuropathy, higher therapeutic dosing may be used: 100 mg daily for about 3 weeks followed by a maintenance dose of 30 mg daily is an FDA-cited regimen for treating drug-induced deficiency, after which prophylactic dosing resumes; this is distinct from routine prophylaxis and should be reserved for deficiency states [^113omLBo] [^116je9Bv]. Let me reconsider whether to recommend this upfront for a 41 kg adult without neuropathy; no, routine prophylaxis should remain 25–50 mg/day unless deficiency is documented or strongly suspected [^116LLnYh].

> Hold on, I should verify that I'm not conflating prophylaxis with overdose management. For acute isoniazid poisoning, the antidote is high-dose IV pyridoxine dosed gram-for-gram equal to the ingested INH amount, with adult protocols often starting 4–5 g IV if dose is unknown and repeating until seizures stop; this is a rescue therapy and is not used for routine prophylaxis in therapeutic INH use [^11172MYV] [^1168UGE5]. I need to ensure I don't mistakenly apply overdose dosing to a patient on therapeutic INH; correct, overdose protocols are irrelevant for prophylaxis in this scenario [^11172MYV].

> Next, I should review safety and interactions. Pyridoxine is generally safe at prophylactic doses, but chronic high-dose exposure above roughly 50–100 mg/day can cause sensory neuropathy; drug–drug interactions include reduction of levodopa efficacy, and isoniazid itself increases pyridoxine requirements, which supports routine co-administration during INH therapy [^116T3FqL] [^114aRpn5]. Let me double-check that our prophylactic range stays within the safety window; yes, 25–50 mg/day is below the chronic neurotoxic threshold reported in case literature, though individual susceptibility varies [^116T3FqL].

> Putting this together for a 41 kg adult on standard-dose INH, I should confirm the final recommendation. The appropriate prophylactic pyridoxine dose is 25–50 mg orally once daily, with 25 mg reasonable for average risk and 50 mg favored in the presence of additional risk factors such as low body weight, malnutrition, diabetes, alcohol use, slow acetylator status, or concomitant neurotoxic drugs; weight-based adjustment is not required for adults in routine prophylaxis, and exceeding 50 mg/day is not recommended for prophylaxis absent a specific indication [^116LLnYh] [^112nfNNG] [^114pC1Y7]. If the patient is on 3HP, consider 50 mg once weekly per guideline allowance, but many clinicians prefer daily 25–50 mg in lower-weight adults to mitigate neurotoxicity risk, recognizing the fixed 900 mg INH dose may be supratherapeutic for smaller bodies [^11442oyd] [^114pRCGn].

> Finally, I should confirm monitoring and follow-up. Counsel on neuropathy symptoms such as paresthesias, gait imbalance, or sensory loss, and reassess at regular intervals during INH therapy. If neuropathy develops, treat deficiency with 100 mg daily for 3 weeks followed by 30 mg daily maintenance while continuing INH when feasible, and consider NAT2 acetylator status or therapeutic drug monitoring in high-risk settings to individualize INH exposure and pyridoxine strategy [^113omLBo] [^116EHNkG] [^112wRsfm]. Hold on, I should verify that routine labs for pyridoxine are not required. Correct, clinical monitoring suffices in most programs, with deficiency treatment guided by symptoms rather than routine levels [^notfound].

---

For a 41 kg patient on isoniazid, the recommended pyridoxine dose is **25–50 mg orally once daily** [^112nfNNG] to prevent peripheral neuropathy [^116LLnYh]. This fixed adult dose applies regardless of weight, and **no weight-based adjustment is needed**. If the patient is a child, use **1–2 mg/kg/day (max 25–50 mg/day)** [^112Q8xQ1] [^112BKCQG]. Pyridoxine should be continued for the entire duration of isoniazid therapy.

---

## Recommended pyridoxine dose for adults

- **Standard adult dose**: 25–50 mg orally once daily [^112nfNNG] [^116LLnYh].
- **Fixed dose**: The adult dose is fixed and does not require weight-based adjustment [^112nfNNG].
- **Duration**: Continue pyridoxine supplementation for the entire duration of isoniazid therapy [^112nfNNG].

---

## Recommended pyridoxine dose for pediatric patients

For pediatric patients, the dose is **weight-based**: 1–2 mg/kg orally once daily (maximum 25–50 mg/day) [^112Q8xQ1] [^112BKCQG]. For a 41 kg child, this equates to **41–82 mg/day**, but the maximum recommended dose is **50 mg/day** [^112Q8xQ1] [^112BKCQG]. Therefore, the appropriate pediatric dose for a 41 kg child is **25–50 mg/day**.

---

## Clinical evidence supporting pyridoxine supplementation

Pyridoxine supplementation is recommended to prevent **isoniazid-induced peripheral neuropathy**, which results from inhibition of pyridoxine metabolism [^114nV4PM] [^113bEwGn]. Clinical guidelines from the American Thoracic Society (ATS), Centers for Disease Control and Prevention (CDC), and Infectious Diseases Society of America (IDSA) recommend pyridoxine supplementation for all adults receiving isoniazid therapy [^112nfNNG].

---

## Special considerations

- **Malnutrition**: Patients with poor nutritional status may be at increased risk of pyridoxine deficiency and may benefit from supplementation [^112sEfvz] [^115Et9Cm].
- **Alcohol use**: Patients with alcohol use disorder are at increased risk of peripheral neuropathy and may benefit from pyridoxine supplementation [^115Et9Cm].
- **Pregnancy**: Pregnant women receiving isoniazid should receive pyridoxine supplementation to prevent maternal and fetal neurotoxicity [^117JSaF8].

---

## Pyridoxine dosing recommendations

| **Patient population** | **Recommended pyridoxine dose** |
|-|-|
| Adults (≥ 13 years) | 25–50 mg orally once daily |
| Pediatric patients (≤ 12 years) | 1–2 mg/kg/day (max 25–50 mg/day) |
| Pregnant women | 25–50 mg orally once daily |

---

For a 41 kg patient receiving isoniazid, the recommended pyridoxine dose is **25–50 mg orally once daily**. This fixed adult dose applies regardless of weight, and no weight-based adjustment is necessary.

---

## References

### Treatment of drug-resistant tuberculosis. An official ATS / CDC / ERS / IDSA clinical practice guideline [^111qX6JF]. American Journal of Respiratory and Critical Care Medicine (2019). High credibility.

ATS/CDC/ERS/IDSA — Linezolid dosing, safety, and interactions in multidrug-resistant tuberculosis (MDR-TB): Adverse effects, especially myelosuppression, are noted to be common at the currently recommended dose of 10 mg/kg twice daily in children < 10 years of age, and strict clinical monitoring for peripheral neuropathy, optic neuritis, anemia, and leukopenia is necessary during long-term use; in adults, lowering the dose from 600 mg/d to 300 mg/d after culture conversion reduced toxicity, and some patients with visual toxicity can avoid recurrence with a reduced dose of linezolid of 300 mg daily. For children, one modeling study reported that a linezolid dose of 15 mg/kg in full-term neonates and infants aged ≤ 3 months and 10 mg/kg in toddlers, administered once daily, achieved cumulative fraction of response of ≥ 90%, with < 10% achieving linezolid area under the concentration–versus–time curve (AUC) of 0 to 24 associated with toxicity, and WHO and the Sentinel Project recommend pediatric doses of linezolid is 15 mg/kg once daily for children < 15 kg and 10 to 12 mg/kg once daily for those weighing > 15 kg. Linezolid should generally not be administered to patients taking serotonergic agents, such as monoamine oxidase inhibitors, because of the potential for serious CNS reactions, such as serotonin syndrome. Administration of linezolid concurrently with a selective serotonin reuptake inhibitor can lead to serious reactions, such as serotonin syndrome or neuroleptic malignant syndrome–like reactions, and it is common practice for patients on linezolid to be prescribed vitamin B6.

---

### Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV [^114pC1Y7]. HIV.gov (2025). High credibility.

Latent TB infection (LTBI) — isoniazid (INH) dosing and pyridoxine coadministration includes: Use INH with pyridoxine 25–50 mg PO daily (50 mg once weekly if used with 3HP); for 3HP (weekly INH + rifapentine x 12 weeks), give 15 mg/kg PO once weekly (900 mg maximum); for 3HR (daily INH + rifampin x 3 months), or 1HP (daily INH + rifapentine x 4 weeks), or INH alone (daily INH x 6–9 months), give 300 mg PO daily.

---

### Renal association clinical practice guideline in post-operative care in the kidney transplant recipient [^115EhMaN]. BMC Nephrology (2017). Low credibility.

Guideline 8.8 – KTR: post-transplant infection prophylaxis

All patients should receive 3–6 months of treatment with co-trimoxazole 480 mg daily (1B)
Oral antifungal prophylaxis should be administered for 1 week month after transplantation (2C)
In selected patients, prophylaxis against mycobacterium tuberculosis with daily isoniazid (supplemented with pyridoxine) should be instituted for 6 months after transplantation (2C)

Rationale

In addition to benefit for PCP, there is good evidence that co-trimoxazole provides effective prophylaxis against urinary tract infections after renal transplantation. Alternatives include cephalosporins and fluoroquinolones. Alternative agents against pneumocystis jirovecii include dapsone, atovaquone or aerosolized pentamidine.

Candida infection is common after renal transplantation and can cause considerable morbidity. It is usually acquired from colonisation of the oral mucosa and so topical oral preparations offer a simple form of prevention without the potential toxicity of systemic preparations.

Tuberculosis in KTRs is usually due to reactivation of quiescent disease under the influence of immunosuppression. In other immunosuppressed populations treatment of latent tuberculosis prevents progression to clinically active tuberculosis. A recent Cochrane Database review recommended prophylaxis with isoniazid (for up to 1 year) in selected recipients at high risk of tuberculosis (based on prior infection or exposure, or patients whose country of origin has a high incidence of tuberculosis infection) with careful monitoring of liver function, especially in patients who are hepatitis B and C positive.

Guideline 8.9 – KTR: Hepatitis E Virus

We recommend that Hepatitis E Virus (HEV)-screened blood components should be given to all KTR (1C)

Rationale

There has been an increase in the number of reports of cases of hepatitis E virus (HEV) in the United Kingdom. The infection is usually mild and self- limiting in the immunocompetent but there is increasing evidence that HEV infection in patients receiving immunosuppression may lead to persistent infection, which may lead to chronic hepatitis and cirrhosis. HEV may be transmitted through the use of blood and blood products, through transplantation and through diet (especially inadequately cooked pork and pork products such as sausages and offal). Liver tests may be normal or show mild hepatitis. The favoured diagnostic test is by HEV polymerase chain reaction. Liver biopsy may show histology. Conventional management of HEV infection is review immunosuppression and reduce or minimise immunosuppressive burden where possible. If there is no serological evidence e clearance within 3 months, consider a 3-months course of Ribavarin (note this use is off licence).

---

### Isoniazid [^114z2c1M]. FDA (2025). Medium credibility.

For Preventative Therapy of Tuberculosis

Before isoniazid preventive therapy is initiated, bacteriologically positive or radiographically progressive tuberculosis must be excluded. Appropriate evaluations should be performed if extra pulmonary tuberculosis is suspected.

Adults over 30 kg: 300 mg per day in a single dose.

Infants and Children: 10 mg/kg (up to 300 mg daily) in a single dose.

In situations where adherence with daily preventative therapy cannot be assured, 20 mg/kg to 30 mg/kg (not to exceed 900 mg) twice weekly under the direct observation of a health care worker at the time of administration8.

Continuous administration of isoniazid for a sufficient period is an essential part of the regimen because relapse rates are higher if chemotherapy is stopped prematurely. In the treatment of tuberculosis, resistant organisms may multiply and the emergence of resistant organisms during the treatment may necessitate a change in the regimen.

For following patient compliance: the Potts-Cozart test9, a simple colorimetric6method of checking for isoniazid in the urine, is a useful tool for assuring patient compliance, which is essential for effective tuberculosis control. Additionally, isoniazid test strips are also available to check patient compliance.

Concomitant administration of pyridoxine (B6) is recommended in the malnourished and in those predisposed to neuropathy (e.g., alcoholics and diabetics).

---

### Regressive pyridoxine-induced sensory neuronopathy in a patient with homocystinuria [^116T3FqL]. BMJ Case Reports (2018). Medium credibility.

Pyridoxine (vitamin B6) is an essential vitamin playing a crucial role in amino acid metabolism. Pyridoxine is used for isoniazid side-effects prevention, pyridoxine-dependent epilepsy treatment and cystathionine beta-synthase deficiency (homocystinuria) treatment. However, vitamin B6 hypervitaminosis is neurotoxic and may provoke a progressive sensory neuronopathy (sensory ganglionopathy), usually when daily uptake is above 50mg. We describe the case of a 30-year-old patient with homocystinuria who was treated with pyridoxine 1250–1750mg/day for 20 years and developed progressive sensory neuropathy with ataxia and impaired sensation in the extremities. Electrodiagnostic testing demonstrated non-length-dependent abnormalities of sensory nerve potentials, and sensory ganglionopathy was diagnosed. Pyridoxine dosage was reduced to 500mg/day, resulting in the disappearance of sensory symptoms and ataxia, and the normalisation of sensory nerve potentials. Our case indicates that pyridoxine-induced sensory ganglionopathy may be reversible, even after prolonged ingestion of high doses of vitamin B6 for more than 20 years.

---

### Late presentation with HIV in Africa: phenotypes, risk, and risk stratification in the REALITY trial [^1123DSEe]. Clinical Infectious Diseases (2018). Low credibility.

METHODS

REALITY recruited previously untreated adults and children aged ≥ 5 years with a CD4 count < 100 cells/µL from 8 centers in Kenya, Malawi, Uganda, and Zimbabwe. Pregnancy or breastfeeding were trial exclusion criteria. Participants were randomized 1:1 to each of 12 weeks of raltegravir vs no raltegravir; enhanced prophylaxis vs standard prophylaxis (cotrimoxazole); and 12 weeks of ready-to-use supplementary food vs standard nutritional support, together with WHO-recommended combination ART. Enhanced prophylaxis consisted of cotrimoxazole plus isoniazid, pyridoxine, and fluconazole for 12 weeks, azithromycin for 5 days, and a single dose of albendazole. Adults and children's guardians gave written informed consent; older children gave additional assent following national guidelines. The trial was approved by ethics committees in Zimbabwe, Uganda, Malawi, Kenya, and the United Kingdom.

At screening and enrollment, patients underwent a physical examination including height, weight, mid-upper arm circumference (MUAC), body composition assessment by bioimpedance analysis (TANITA BC-420MA), and assessment for WHO stage 3/4 events, including tuberculosis symptom screen and diagnostic tests as indicated. Concomitant medications, including reason for prescription, were also recorded at both visits. At enrollment, blood pressure and grip strength (Takei 5401 Hand Grip Dynamometer) were measured, and participants were administered a symptom checklist and EuroQol 5 Dimensions (EQ-5D) questionnaire. Full blood count, tests of renal and liver function, and lymphocyte subsets were assayed at screening and enrollment in real time and samples were stored at enrollment for retrospective HIV viral load (VL) assays.

---

### Prevalence of neurotoxicity symptoms among postpartum women on isoniazid preventive therapy and efavirenz-based treatment for HIV: an exploratory objective of the IMPAACT P1078 randomized trial [^111UFXcL]. BMC Pregnancy and Childbirth (2023). Medium credibility.

Methods

Study design

IMPAACT P1078 TB APPRISE [ClinicalTrials.gov number, NCT01494038, first registered on 16/12/2011]was a Phase IV, randomized, double-blind, placebo-controlled non-inferiority study that compared the overall safety and risks and benefits of immediate versus deferred IPT in pregnant women living with HIV, on ART and their infants, enrolled at ≥ 14 through ≤ 34 weeks gestation, at high risk for TB. It was a multi-site study performed in Thailand, Haiti, India, Uganda, Tanzania, South Africa, Botswana and Zimbabwe. At study entry, women were randomized in a 1:1 ratio to initiate oral IPT either during pregnancy (Immediate INH) or at week 12 after delivery (Deferred INH). Women in the Immediate arm were given 300 mg of INH daily initiated at study entry and continued for 28 weeks followed by a Placebo for INH until 40 weeks postpartum. Women in the Deferred arm were given a Placebo for INH initiated at study entry followed by 300 mg of INH daily initiated at 12 weeks postpartum and continued for 28 weeks. All women were provided with pyridoxine (vitamin B 6) and prenatal multivitamins from study entry until 40 weeks postpartum. Non-study standard-of-care Cotrimoxazole prophylaxis was provided to women with CD4 counts below 350 cells/mm. Women and their infants were followed through 48 weeks postpartum. Randomization was stratified by site and gestational age (≥ 14 weeks to < 24 weeks or ≥ 24 weeks to ≤ 34 weeks). Full details of the P1078 study design have been described elsewhere and can be found here:

The analysis of neurocognitive toxicity of INH and EFV was informed by questions from three assessments added to protocol Version 2.0. The Patient Health Questionnaire 9 (PHQ-9) captured depression symptoms over the previous two weeks. A three-item questionnaire adapted from Simioni et al. assessed cognitive complaints. Finally, several questions were adapted from the Pittsburgh Sleep Quality Index (PSQI) to assess sleep habits during the past month. Because the neurocognitive toxicity evaluations were not included until partway through study implementation, these evaluations were not available for every woman at every study visit. However, peripheral neuropathy, which was evaluated using the Brief Peripheral Neuropathy Screening (BPNS) tool, was assessed throughout the duration of the study.

---

### Chronic dialysis, NAT2 polymorphisms, and the risk of isoniazid-induced encephalopathy-case report and literature review [^112wRsfm]. BMC Nephrology (2017). Low credibility.

Conclusions

In conclusion, the combination of end-stage renal disease, removal of pyridoxal phosphate by hemodialysis, and deleterious NAT2 polymorphisms, contributed to the severe toxicity of isoniazid in our patient. Drug withdrawal and administration of high doses of pyridoxine rapidly reversed drug toxicity. Physicians should be aware of the increased risk of isoniazid toxicity in patients on dialysis and in those with a slow acetylator phenotype conferred by NAT2 polymorphisms. Adaptation of prescription – either with higher doses of pyridoxine or decreased doses of isoniazid, respectively – has been suggested to effectively reduce the risk of potentially life-threatening toxicity of isoniazid, while avoiding treatment failure. Future studies will need to validate NAT2 genotype-guided drug dosage of isoniazid as a safe and appropriate alternative to standard dose regimen.

---

### Isoniazid plasma concentrations in a cohort of South African children with tuberculosis: implications for international pediatric dosing guidelines [^116cLKrV]. Clinical Infectious Diseases (2009). Low credibility.

Background

In most countries with a high burden of tuberculosis, children with tuberculosis are prescribed isoniazid at dosages of 4–6 mg/kg/day, as recommended by international authorities.

Methods

We studied isoniazid concentrations in 56 hospitalized children (median age, 3.22 years; interquartile range [IQR], 1.58–5.38 years) who received isoniazid daily (median dosage, 5.01 mg/kg/day; range, 2.94–15.58 mg/kg/day) as part of antituberculosis treatment. At 1 and 4 months after initiation of treatment, isoniazid concentrations were measured in plasma samples at 0.75, 1.5, 3, 4, and 6 h after a treatment dose, to describe pharmacokinetic measures by using noncompartmental analysis. The effects of dose in milogram per kilogram, acetylator genotype, age, sex, and clinical diagnosis of kwashiorkor and human immunodeficiency virus (HIV) infection on isoniazid concentrations were evaluated.

Results

Median peak concentrations of isoniazid in children prescribed a dose of 4–6 mg/kg were 58% lower than those in children prescribed a dose of 8–10 mg/kg (2.39 mg/L [IQR, 1.59–3.40] vs. 5.71 mg/L [IQR, 4.74–7.62]). Peak concentrations were < 3 mg/L in 70% of children prescribed a dose of 4–6 mg/kg. In contrast, children prescribed a dose of 8–12 mg/kg achieved peak concentrations approximating those in adults treated with 300 mg of isoniazid daily. Intermediate or fast acetylator genotype independently predicted a 38% (95% confidence interval [CI] 21%-51%) reduction in peak concentrations, compared with the slow-acetylator genotype. Each 1-mg/kg increase in the dose and each year increase in age were associated with increases in peak concentrations of 21% (95% CI, 16%-25%) and 6% (95% CI, 3%-10%), respectively.

Conclusions

Younger children require higher doses of isoniazid per kilogram of body weight to achieve isoniazid concentrations similar to those in adults. A daily isoniazid dose of 8–12 mg/kg should be recommended.

---

### Priorities for decreasing morbidity and mortality in children with advanced HIV disease [^116wJhJJ]. Clinical Infectious Diseases (2018). Low credibility.

Overall, data on the use of a package of interventions in children > 5 years of age are limited and no data are available in children < 5 years old.

Based on previous recommendations included in the WHO 2016 consolidated ART guidelines, the package of screening and prophylaxis interventions for children consists of screening and diagnosis of TB, and preventive measures such as cotrimoxazole prophylaxis and isoniazid prophylaxis. However, cryptococcal antigen screening and fluconazole prophylaxis are not recommended due to limited data and the lower disease burden, reducing the likely cost-effectiveness of these approaches.

Increased pill or syrup burden is a particular concern for children and, where possible, fixed-dose combination formulations should be utilized, including the new fixed-dose combination of cotrimoxazole, isoniazid, and pyridoxine, which is a scored tablet and has shown good bioavailability in children. A half-dose scored tablet is still needed for children < 5 years of age. Whether the current package (Table 1) is sufficiently adapted to the specific leading causing of mortality in children remains an important question for future research, particularly to address the high rates of bacteremia in the first 3 months of treatment. Approaches that may decrease early death and morbidity include presumptive treatment of or additional prophylaxis for bacterial infections, availability of ganciclovir, early treatment of hematological disorders, prompt treatment of oral/esophageal Candida, oral rehydration for diarrhea, and more frequent home visits/follow-up or growth monitoring.

Table 1.
Components of the Package of Care for Human Immunodeficiency Virus (HIV)–Infected Adolescents and Children With Advanced HIV Disease

Finally, routine interventions recommended by WHO for the general pediatric population such as deworming, malaria prophylaxis, and vitamin A supplementation should all be provided. Childhood vaccinations may also prevent bacteremia, diarrhea, and pneumonia and should be reinforced.

Overall, it remains critical to ensure that interventions to minimize early mortality are implemented in countries with a high burden of pediatric HIV.

---

### Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America [^117JSaF8]. MMWR: Recommendations and Reports (2009). Medium credibility.

Opportunistic infection drugs during pregnancy (Table 8) — Isoniazid: It is not teratogenic in animals but may pose a possible increased risk of hepatotoxicity during pregnancy; prophylactic pyridoxine 50 mg/day should be given to prevent maternal and fetal neurotoxicity, and it is used for active TB and for prophylaxis for exposure or skin test conversion.

---

### Pyridoxine hydrochloride injection, USP… [^112CJkJP]. FDA (DailyMed) (2025). Medium credibility.

metabolite is excreted in the urine. The need for pyridoxine increases with the amount of protein in the diet. The tryptophan load test appears to uncover early vitamin B deficiency by detecting xanthinurea. The average adult minimum daily requirement is about 1. 25 mg. The 6 6 6 6 6. xanthinurea. The average adult minimum daily requirement is about 1. 25 mg. The "Recommended Dietary Allowance" of the National Academy of Sciences is estimated to be as much as 2. 2 mg for adults and
2. 5 mg for pregnant and lactating women. The. Paresthesia, somnolence, and low serum folic acid levels have been reported. DRUG ABUSE AND DEPENDENCE: Symptoms of dependence have been noted in adults given only 200 mg daily, followed by withdrawal. OVERDOSAGE: Pyridoxine given to animals in amounts of 3 to 4 g/kg of body weight produces. convulsions and death. In man, a dose of 25 mg/kg of body weight is well tolerated.

DOSAGE AND ADMINISTRATION: Pyridoxine Hydrochloride Injection may be administered intramuscularly or intravenously. In cases of dietary deficiency, the dosage is 10 to 20 mg daily for 3. weeks. Follow-up treatment is recommended daily for several weeks with an oral therapeutic multivitamin preparation containing 2 to 5 mg pyridoxine. Poor dietary habits should be corrected, and an adequate, well balanced diet should be prescribed. The vitamin B dependency syndrome may require a therapeutic dosage of as much as. 600 mg a day and a daily intake of 30 mg for life. In deficiencies due to INH, the dosage is 100 mg daily for 3 weeks followed by a 30 mg maintenance dose daily. In poisoning caused by ingestion of more than 10 g of INH, an equal amount of 6. pyridoxine should be given — 4 g intravenously followed by 1 g intramuscularly every 30 minutes.

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. HOW SUPPLIED: Pyridoxine Hydrochloride Injection, USP is supplied as:

---

### Efficacy of isoniazid prophylaxis in patients with systemic lupus erythematosus receiving long term steroid treatment [^113z7uGk]. Annals of the Rheumatic Diseases (2002). Low credibility.

Objective

To study the efficacy of isoniazid prophylaxis (INHP) in patients with systemic lupus erythematosus (SLE) receiving long term glucocorticosteroid treatment.

Patients and Methods

Treatment with INHP (5 mg/kg/day, max 300 mg/day) together with pyridoxine 10 mg/day for one year was started in all patients with SLE seen between January 1994 and December 1999 and followed up thereafter. Clinical examination and chest radiography were carried out in all patients before the start of INHP treatment. A liver profile was obtained only if liver toxicity was suspected owing to nausea, loss of appetite, and icterus. Only the data of those patients who completed the INHP treatment or who were withdrawn owing to toxicity have been analysed. This was compared with the results of an earlier study of the incidence of tuberculosis (TB) in patients with SLE not receiving INHP.

Results

Ninety seven patients were included, of whom 95 completed one year's treatment with INHP. Treatment was discontinued in two owing to toxicity: hepatitis in one and peripheral neuropathy in one, at eight and 10 months, respectively. One patient developed TB within one month of starting INHP. Seventy patients were followed up further for at least one year (mean 26.4 months, range 12–60 months) after completion of the INHP treatment. During this period one patient developed TB after one month. No deaths due to TB or hepatitis occurred. In comparison with earlier series the incidence of TB decreased from 11% to 2%, a reduction of 82%. The cost of treatment for each case of TB prevented in the first year was 5800 rupees.

Conclusion

INHP is safe and effective in SLE.

---

### Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV [^1126dEvs]. HIV.gov (2025). High credibility.

Alternative therapy for patients receiving an efavirenz-based ARV regimen — stated as only for patients receiving an efavirenz-based ARV regimen and not recommended for extrapulmonary TB — details rifapentine-based regimens with defined durations. Intensive Phase (8 weeks): Isoniazid plus rifapentine 1,200 mg plus moxifloxacin 400 mg plus pyrazinamide plus pyridoxine 25–50 mg PO daily (AI). Continuation Phase (9 weeks): Isoniazid plus rifapentine 1,200 mg plus moxifloxacin 400 mg plus pyridoxine 25–50 mg PO daily (AI).

---

### The 3 HP regimen for tuberculosis preventive treatment: safety, dosage and related concerns during its large-scale implementation in countries like India [^112pCLHZ]. The Lancet Regional Health: Southeast Asia (2024). High credibility.

In the absence of any formal RCT of the 3 HP regimen in India or a comparable setting, and the paucity of data on safety from India, there are 3 key issues related to the safety of the regimen in India. First, the dose of INH in this WHO recommended and NTEP endorsed 3 HP regimen is inappropriate for the weights in Indian subjects, that will result in exceeding the maximum recommended dose in a significant proportion of subjects. Second, the acetylator status of the Indian population needs to be taken into consideration. Finally, there is a lack of availability or even a recommendation for requirement for use of pyridoxine as an adjunct to the administration of this regimen.
1 Dosing of isoniazid in the 3 HP regimen and its implications.

In this viewpoint article I limit the discussion to the doses of INH in 3 HP to adults as in children the doses are weight-appropriate and there are other alternatives like 3 HR that are being used. In the current WHO guidelines for TPT with 3 HP, in subjects > 14 years and in the weight range of ≥ 30 kg to > 70 kg a uniform weekly dose of 900 mg (as 3 tablets of 300 mg each) isoniazid has been recommended, based on the dose in the PREVENT trial. This recommendation goes against the principle of weight-based dosing of anti-tubercular drugs that has been used in guidelines for treatment of tuberculosis.

---

### Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV [^114rPYPB]. HIV.gov (2025). High credibility.

Mycobacterium tuberculosis infection (TB) (i.e., treatment of latent TB infection [LTBI]) — Indications include a positive screening test for LTBI with no evidence of active TB and no prior treatment for active TB or LTBI (AI), or close contact with a person with infectious TB with no evidence of active TB regardless of screening test results and CD4 count (AII). Preferred regimens include 3HP: rifapentine plus INH 15 mg/kg (900 mg maximum) plus pyridoxine 50 mg PO once weekly for 12 weeks (AI) with weight-based rifapentine dosing of 25.1–32 kg: 600 mg PO once weekly, 32.1–49.9 kg: 750 mg PO once weekly, and > 50 kg: 900 mg PO once weekly; and 3HR: INH 300 mg plus rifampin 600 mg plus pyridoxine 25–50 mg PO daily for 3 months (AI). The note specifies 3HP is recommended only for virally suppressed persons receiving EFV, RAL, or once daily DTG-based ARV regimen (AII). Alternative regimens include INH 300 mg plus pyridoxine 25–50 mg PO daily for 6–9 months (AII), 4R: rifampin 600 mg PO daily for 4 months (BI), and 1HP: rifapentine plus INH 300 mg plus pyridoxine 25–50 mg PO once daily for 4 weeks (BI) with weight-based rifapentine dosing of < 35 kg: 300 mg PO once daily, 35–45 kg: 450 mg PO once daily, and > 45 kg: 600 mg PO once daily; additionally, 1HP is recommended only for patients receiving an efavirenz-based ARV regimen (BI), and for persons exposed to drug-resistant TB, anti-TB drugs should be selected after consultation with experts and public health authorities (AIII).

---

### Pyridoxine-dependent seizures responding to extremely low-dose pyridoxine [^116iYn4Q]. Developmental Medicine and Child Neurology (2001). Low credibility.

We report on a male infant with pyridoxine dependency and seizures from birth, controlled with pharmacological doses of pyridoxine at 4 months of age. Seizures stopped between 30 and 80 days of age when very-low doses of pyridoxine were given in a multivitamin supplement. Daily dose was 0.5 mg that corresponded to 0.08 to 0.16 mg/kg/day when weight gain is considered. In previous reports doses have ranged from 0.2 to 30 mg/kg/day. Another distinctive feature was that this infant went into a coma and developed hypotonia and irregular breathing when pyridoxine was given by enteral tube which has usually been reported when the vitamin is given intravenously. Use of low doses of pyridoxine in multivitamin supplements could be a confounding factor for early diagnosis and appropriate treatment of pyridoxine-dependent seizures.

---

### Chronic dialysis, NAT2 polymorphisms, and the risk of isoniazid-induced encephalopathy-case report and literature review [^116K6CMf]. BMC Nephrology (2017). Low credibility.

Background

Isoniazid is the most widely used anti-tuberculosis agent, yet it may lead to life-threatening complications.

Case presentation

Here we report the case of a chronic hemodialysis patient who developed severe encephalopathy after the start of isoniazid. Blood levels of isoniazid were elevated, and acetyl-isoniazid over isoniazid ratio was decreased 3 h after intake of the medication, suggesting that a slow acetylator phenotype may have contributed to drug toxicity, in addition to pyridoxal phosphate removal by dialysis. This hypothesis was confirmed by sequencing of NAT2, the gene responsible for isoniazid elimination, and identification of NAT2 polymorphisms compatible with a slow acetylator phenotype. Isoniazid withdrawal along with supplementation using high doses of pyridoxine successfully reversed the drug toxicity. Isoniazid toxicity occurs in populations at risk, including patients with chronic kidney failure or NAT2 polymorphisms, who have a disturbed metabolism of pyridoxine or isoniazid, respectively, and those on renal replacement therapies, in whom pyridoxal phosphate – the active metabolite of pyridoxine – is inadvertently removed by dialysis.

Conclusions

Physicians should be aware of the increased risk of isoniazid toxicity in patients on dialysis and in those with a slow acetylator phenotype conferred by NAT2 polymorphisms. Adaptation of prescription – either with higher doses of pyridoxine or decreased doses of isoniazid, respectively – has been suggested to reduce the risk of potentially life-threatening toxicity of isoniazid.

---

### Guidelines for the prevention and treatment of opportunistic infections among HIV-exposed and HIV-infected children: recommendations from CDC, the National Institutes of Health, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics [^114XR46X]. MMWR: Recommendations and Reports (2009). Medium credibility.

Adjunctive treatments in HIV-infected children with TB include co-trimoxazole, pyridoxine, and corticosteroids: Co-trimoxazole prophylaxis is listed. Pyridoxine 1–2 mg/kg/ body weight/day (maximum 25–50 mg/day) with isoniazid or cycloserine/teridizone or, if malnourished; pyridoxine supplementation is recommended for exclusively breastfed infants and for children and adolescents on meat- and milk-deficient diets; including all symptomatic HIV-infected children; and pregnant adolescents and women. Corticosteroids (2 mg/kg body weight per day of prednisone [maximum, 60 mg/day] or its equivalent for 4–6 weeks) are noted.

---

### Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America [^114wXrJp]. MMWR: Recommendations and Reports (2009). Medium credibility.

Tuberculosis (TB) in pregnancy — diagnosis and maternal–fetal considerations include that the diagnostic evaluation for TB disease in pregnant women is the same as for non-pregnant adults, and chest radiographs with abdominal shielding are recommended and result in minimal fetal radiation exposure. While treatment with isoniazid should be delayed until after delivery, if the risk of progression to active TB disease is considered to outweigh the risk of adverse birth outcomes with isoniazid and isoniazid is prescribed, frequent monitoring is needed, and pregnant women receiving isoniazid should receive daily pyridoxine supplementation as they are at risk of isoniazid-associated peripheral neuropathy. In one study of 107 women with active TB disease during pregnancy in South Africa, M. tuberculosis was detected in 16% of neonates (n = 16) tested within the first 3 weeks of life (12 by culture and 4 by smear microscopy).

---

### High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial [^1135YpkL]. The Lancet: Infectious Diseases (2017). Medium credibility.

Procedures

All drugs were oral, given once daily, 7 days per week. Control treatment consisted of standard dose rifampicin (10 mg/kg [range 8·1–11·8 mg/kg]), isoniazid (5 mg/kg [4·1–5·9 mg/kg]), pyrazinamide (25 mg/kg [21·6–31·6 mg/kg]), and ethambutol (15–20 mg/kg [14·9–21·7 mg/kg]) for 8 weeks, followed by 18 weeks of standard dose rifampicin and isoniazid. Experimental treatments consisted of rifampicin 35 mg/kg, plus standard dose isoniazid, pyrazinamide, and ethambutol (arm RIF 35 HZE); rifampicin 10 mg/kg, standard dose isoniazid and pyrazinamide, and SQ109 300 mg (arm RIFQHZ); rifampicin 20 mg/kg, standard dose isoniazid and pyrazinamide, and SQ109 300 mg (arm RIF 20 QHZ); or rifampicin 20 mg/kg, standard dose isoniazid and pyrazinamide, and moxifloxacin 400 mg (arm RIF 20 MHZ). Experimental treatment was given for 12 weeks, followed by 14 weeks of standard dose isoniazid and rifampicin. Pyridoxine (vitamin B6, 25 mg) was given in the morning to all patients throughout the trial. The control regimen was weight banded according to the South African tuberculosis treatment guidelinesand implemented in both participating countries (appendix p 10). Higher doses of rifampicin were adapted to these weight bands (appendix). All drugs were self-administered except for days of clinic visits, where administration was directly observed. Participants were advised to take their drugs in the morning after a light breakfast and with a glass of water.

---

### Pyridoxine hci [^113omLBo]. FDA (2024). Medium credibility.

DOSAGE & ADMINISTRATION

Pyridoxine Hydrochloride Injection may be administered intramuscularly or intravenously. In cases of dietary deficiency, the dosage is 10 to 20 mg daily for 3 weeks. Follow-up treatment is recommended daily for several weeks with an oral therapeutic multivitamin preparation containing 2 to 5 mg pyridoxine. Poor dietary habits should be corrected, and an adequate, well balanced diet should be prescribed.

The vitamin B6 dependency syndrome may require a therapeutic dosage of as much as 600 mg a day and a daily intake of 30 mg for life.

In deficiencies due to INH, the dosage is 100 mg daily for 3 weeks followed by a 30 mg maintenance dose daily.

In poisoning caused by ingestion of more than 10 g of INH, an equal amount of pyridoxine should be given — 4 g intravenously followed by 1 g intramuscularly every 30 minutes.

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.

---

### Pyridoxine hci [^112X9ytz]. FDA (2024). Medium credibility.

ADVERSE REACTIONS

Paresthesia, somnolence, and low serum folic acid levels have been reported.

---

### The 3 HP regimen for tuberculosis preventive treatment: safety, dosage and related concerns during its large-scale implementation in countries like India [^113bEwGn]. The Lancet Regional Health: Southeast Asia (2024). High credibility.

Isoniazid is metabolised by the N-Acetyltransferase 2 gene (NAT2). In case of persons who are slow acetylators, the potential for adverse effects, including hepatotoxicity, are higher. In a study from India, 55% of individuals were found to be slow acetylators, and their plasma isoniazid levels were found to be higher. In a recent study on patients, 58% were slow acetylators and 35% were intermediate acetylators and their median 2-h concentrations were 2–2.5 times that of the 7% who were fast acetylators. The potential for adverse events may be higher in slow acetylators in India who will have even higher INH levels with this high dose isoniazid in the 3 HP regimen. In fact, the WHO recommends a lowering of the isoniazid dosage if the population has a high prevalence of slow acetylators.
3 Isoniazid therapy and the necessity for co-administration of pyridoxine.

Isoniazid therapy can have both acute and chronic toxicity. The common forms of chronic toxicity–peripheral neuropathy (due to pyridoxine deficiency caused by isoniazid) and hepatotoxicity, have been less common with the 12 dose 3 HP regimen. On the other hand, the profile of ADRs reflect acute toxicity of isoniazid with neurological symptoms like dizziness, drowsiness, and general and cardiovascular symptoms like flu-like symptoms, hypotension, with or without features of anaphylaxis. Isoniazid also causes varied neurological manifestations as a result of the functional pyridoxine deficiency, like acute psychosis, seizures, obtundation and even coma, all of which have been show to reverse with pyridoxine in adequate doses. Dizziness has been noted as a prodrome of psychosis.

The pathophysiology of adverse drug reactions with isoniazid partially involve its effect on pyridoxine which is involved in functioning of over 60 enzymes involved in amino acid, carbohydrate, lipid metabolism, including synthesis of neurotransmitters like GABA and glutamate. Isoniazid leads to pyridoxine depletion directly and by inhibiting the phosphokinase enzyme that results in its biologically active form. This has an effect on the metabolic cycle of neurotransmitters, like GABA and glutamate. Isoniazid is also a weak monoamine oxidase inhibitor and can cause serotonin syndrome in the presence of other antidepressants.

---

### Isoniazid (isoniazid 300 mg) [^115Et9Cm]. FDA (2023). Medium credibility.

Treatment of Patients with Multi-Drug Resistant Tuberculosis (MDRTB)

Multiple-drug resistant tuberculosis (i.e., resistance to at least isoniazid and rifampin) presents difficult treatment problems. Treatment must be individualized and based on susceptibility studies. In such cases, consultation with an expert in tuberculosis is recommended.

Directly Observed Therapy (DOT)

A major cause of drug-resistant tuberculosis is patient noncompliance with treatment. The use of DOT can help assure patient compliance with drug therapy. DOT is the observation of the patient by a health care provider or other responsible person as the patient ingests anti-tuberculosis medications. DOT can be achieved with daily, twice weekly or thrice weekly regimens and is recommended for all patients.

For Preventative Therapy of Tuberculosis

Before isoniazid preventive therapy is initiated, bacteriologically positive or radiographically progressive tuberculosis must be excluded. Appropriate evaluations should be performed if extra pulmonary tuberculosis is suspected.

Adults over 30 kg: 300 mg per day in a single dose.

Infants and Children: 10 mg/kg (up to 300 mg daily) in a single dose. In situations where adherence with daily preventative therapy cannot be assured, 20 mg/kg to 30 mg/kg (not to exceed 900 mg) twice weekly under the direct observation of a health care worker at the time of administration8.

Continuous administration of isoniazid for a sufficient period is an essential part of the regimen because relapse rates are higher if chemotherapy is stopped prematurely. In the treatment of tuberculosis, resistant organisms may multiply and the emergence of resistant organisms during the treatment may necessitate a change in the regimen.

For following patient compliance: the Potts-Cozart test9, a simple colorimetric6 method of checking for isoniazid in the urine, is a useful tool for assuring patient compliance, which is essential for effective tuberculosis control. Additionally, isoniazid test strips are also available to check patient compliance.

Concomitant administration of pyridoxine (B6) is recommended in the malnourished and in those predisposed to neuropathy (e.g., alcoholics and diabetics).

---

### Ascorbic acid, thiamine, riboflavin, niacinamide, pyridoxine, folic acid, cobalamin, biotin, pantothenic acid (dialyvite) [^111Rdquu]. FDA (2022). Medium credibility.

CONTRAINDICATIONS

This product is contraindicated in patients with known hypersensitivity to any of the ingredients.

---

### Prevalence of neurotoxicity symptoms among postpartum women on isoniazid preventive therapy and efavirenz-based treatment for HIV: an exploratory objective of the IMPAACT P1078 randomized trial [^111DEuMA]. BMC Pregnancy and Childbirth (2023). Medium credibility.

Background

Isoniazid (INH) Prevention Therapy (IPT) is recommended by the World Health Organization (WHO) for pregnant women living with HIV in countries with high tuberculosis (TB) prevalence, many of whom also receive Efavirenz-based antiretroviral treatment (EFV-ART). Both INH and EFV are independently associated with neurotoxicity. INH-related peripheral neuropathy resulting from its effect on pyridoxine-dependent coenzymes is well described, while INH-related neurocognitive toxicity effects include memory loss, depression, sleep disturbances and acute psychosis. EFV has high cerebral-penetration effectiveness, readily crossing the blood–brain barrier and being concentrated in brain tissue. Central nervous system effects appear soon after initiation of EFV, may be transient, and include abnormal dreams, sleep disturbances, anxiety and depression.

---

### The 3 HP regimen for tuberculosis preventive treatment: safety, dosage and related concerns during its large-scale implementation in countries like India [^115TMgdH]. The Lancet Regional Health: Southeast Asia (2024). High credibility.

The necessity of co-administration of pyridoxine with the 3 HP regimen needs to take into account the dose of isoniazid involved. In persons administered standard dose isoniazid (5 mg/kg daily), pyridoxine supplementation (25–50 mg daily) is co-administered to prevent peripheral neuropathy, in individuals at risk such as those with malnutrition, chronic alcohol dependence, HIV infection, renal failure or diabetes, or who are pregnant or breastfeeding, who can develop neuropathy even with the standard dose. Individuals who are slow acetylators may also be at higher risk. The 3 HP regimen is a high dose isoniazid regimen, as it involves administration of a 3-fold dose of isoniazid (900 mg instead of a maximum of 300 mg), although once weekly. In such a regimen, pyridoxine has been considered necessary in the context of daily use in drug-resistant tuberculosis. The current therapy for drug-susceptible tuberculosis does not provide universal access to pyridoxine in India, although a significant proportion of Indian patients are at risk of INH induced neurotoxicity due to prevalent undernutrition, diabetes and alcohol use. The current WHO guidelines acknowledge that subjects at risk should be given pyridoxine, but also states that the nonavailability of pyridoxine should not be a reason to withhold TPT. The status of pyridoxine deficiency in Indians has not been adequately assessed, but a recent study conducted in apparently healthy adults (less than 5% had low BMI) revealed multiple micronutrient deficiencies of which pyridoxine deficiency in 46% (30% in mild form and 16% in severe form) was the second most common. We would argue that given the population at risk and the higher doses of INH that will be administered it would be prudent to consider pyridoxine as an essential rather than optional adjunct to isoniazid used in the 3 HP regimen.

The RCTs of 3 HP regimen did not administer pyridoxine as a routine and therefore it is not known if some of these adverse events could have been mitigated with co-administration of pyridoxine. A recent randomised clinical trial showed significant reduction of some of the CNS (e.g. dizziness) and GI related adverse drug reactions of quadruple therapy for Helicobacter pylori when pyridoxine was used as an adjunct.

---

### New approaches in the diagnosis and treatment of latent tuberculosis infection [^1173WyyR]. Respiratory Research (2010). Low credibility.

The ATS and CDC guidelines also included 4 months of rifampicin (RMP) alone or 2 months of RMP and pyrazinamide (PZA) as acceptable alternatives for the treatment of LTBI. The RMP alone is recommended for persons intolerant to INH, close contacts of TB cases in which the isolate of M. tuberculosis is resistant to INH or INH resistance is suspected due to the origin of foreign-born persons from countries where INH resistance rates are high. There are several advantages with 4 month daily therapy with RMP such as lower cost, higher adherence to treatment and fewer adverse reactions including hepatotoxicity. However, treatment with RMP alone is not recommended for HIV-seropositive persons on concomitant anti-retroviral therapy as this may lead to the development of acquired rifamycin resistance. Furthermore, active disease in an HIV-infected individual should be ruled out first since monodrug therapy in an undiagnosed active TB disease case may also lead to RMP resistance. However, active TB disease is more difficult to exclude in HIV-infected individuals as they are less likely to have typical features of pulmonary TB and extrapulmonary TB occurs more frequently. The regimen of RMP alone is also not suitable for patients with other underlying conditions such as diabetes.

Treatment of LTBI with RMP + PZA for 4 months is another alternative choice that was advocated by ATS and CDC guidelines in 2000. Although initial studies with 2 months of RMP + PZA in HIV-infected persons were reported to be as effective and safe as INH treatment, several cases of severe liver injury and/or death were reported subsequently with the RMP + PZA regimen resulting in revision of ATS/CDC recommendations in 2003. The revised guidelines advocated that 2 months of RMP + PZA regimen should not generally be offered to HIV-seronegative or HIV-seropositive individuals. A meta-analysis involving six clinical trials comparing the effectiveness of 2 months of RMP + PZA with 6 or 12 months of INH treatment showed that RMP + PZA regimen was associated with increased risk of hepatotoxicity in HIV seronegative persons while the results for HIV-infected persons were inconclusive. However, when the results of 2 months of RMP + PZA were compared with 6 months of INH treatment without supplementation with pyridoxine in HIV-infected persons, the data showed no significant differences in hepatotoxicity in the two sub-groups. The results of some studies suggest that 2 months of RMP + PZA regimen may also be considered when other regimens are unsuitable and monitoring of liver function tests is feasible.

---

### Benefits of combined preventive therapy with co-trimoxazole and isoniazid in adults living with HIV: time to consider a fixed-dose, single tablet coformulation [^113Bh7n8]. The Lancet: Infectious Diseases (2015). Medium credibility.

Antiretroviral therapy (ART) is the main intervention needed to reduce morbidity and mortality and to prevent tuberculosis in adults living with HIV. However, in most resource-limited countries, especially in sub-Saharan Africa, ART is started too late to have an effect with substantial early morbidity and mortality, and in high tuberculosis burden settings ART does not reduce the tuberculosis risk to that reported in individuals not infected with HIV. Co-trimoxazole preventive therapy started before or with ART, irrespective of CD4 cell count, reduces morbidity and mortality with benefits that continue indefinitely. Isoniazid preventive therapy as an adjunct to ART prevents tuberculosis in high-exposure settings, with long-term treatment likely to be needed to sustain this benefit. Unfortunately, both preventive therapies are underused in low-income and high-burden settings. ART development has benefited from patient-centred simplification with several effective regimens now available as a one per day pill. We argue that co-trimoxazole and isoniazid should also be combined into a single fixed-dose pill, along with pyridoxine (vitamin B6), that would be taken once per day to help with individual uptake and national scale-up of therapies.

---

### Chronic dialysis, NAT2 polymorphisms, and the risk of isoniazid-induced encephalopathy-case report and literature review [^111xmdQ9]. BMC Nephrology (2017). Low credibility.

Background

Isoniazid is the most widely used anti-tuberculosis agent, yet it may lead to life-threatening complications.

Case Presentation

Here we report the case of a chronic hemodialysis patient who developed severe encephalopathy after the start of isoniazid. Blood levels of isoniazid were elevated, and acetyl-isoniazid over isoniazid ratio was decreased 3 h after intake of the medication, suggesting that a slow acetylator phenotype may have contributed to drug toxicity, in addition to pyridoxal phosphate removal by dialysis. This hypothesis was confirmed by sequencing of NAT2, the gene responsible for isoniazid elimination, and identification of NAT2 polymorphisms compatible with a slow acetylator phenotype. Isoniazid withdrawal along with supplementation using high doses of pyridoxine successfully reversed the drug toxicity. Isoniazid toxicity occurs in populations at risk, including patients with chronic kidney failure or NAT2 polymorphisms, who have a disturbed metabolism of pyridoxine or isoniazid, respectively, and those on renal replacement therapies, in whom pyridoxal phosphate - the active metabolite of pyridoxine - is inadvertently removed by dialysis.

Conclusions

Physicians should be aware of the increased risk of isoniazid toxicity in patients on dialysis and in those with a slow acetylator phenotype conferred by NAT2 polymorphisms. Adaptation of prescription - either with higher doses of pyridoxine or decreased doses of isoniazid, respectively - has been suggested to reduce the risk of potentially life-threatening toxicity of isoniazid.

---

### Pyridoxine hydrochloride [^114f5mPJ]. FDA (2024). Medium credibility.

INDICATIONS AND USAGE:

Pyridoxine Hydrochloride Injection is effective for the treatment of pyridoxine deficiency as seen in the following:

Inadequate dietary intake.

Drug-induced deficiency, as from isoniazid (INH) or oral contraceptives.

Inborn errors of metabolism, e.g., vitamin B6dependent convulsions or vitamin B6responsive anemia.

The parenteral route is indicated when oral administration is not feasible as in anorexia, nausea and vomiting, and preoperative and postoperative conditions. It is also indicated when gastrointestinal absorption is impaired.

---

### Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV [^11442oyd]. HIV.gov (2025). High credibility.

Treating latent tuberculosis infection (LTBI) — preferred therapy includes: isoniazid 15 mg/kg PO once weekly (900 mg maximum) plus rifapentine (see weight-based dosing below) PO once weekly plus pyridoxine 50 mg PO once weekly (3HP) for 12 weeks (AI), with the note that 3HP is recommended only for virally-suppressed patients receiving an efavirenz-, raltegravir-, or once-daily dolutegravir-based ARV regimen (AII); rifapentine weekly weight-based doses are: Weighing 25.1–32 kg: 600 mg; Weighing 32.1–49.9 kg: 750 mg; Weighing ≥ 50.0 kg: 900 mg (maximum 900 mg). Another preferred regimen is isoniazid 300 mg PO daily plus rifampin 600 mg PO daily plus pyridoxine 25–50 mg PO daily for 3 months (3HR) (AI), with direction to see the dosing recommendations table for ARV drugs not recommended for use with rifampin and those requiring dosage adjustment.

---

### What do we know about micronutrients in critically ill patients? A narrative review [^112sEfvz]. JPEN: Journal of Parenteral and Enteral Nutrition (2025). Medium credibility.

Implementation in clinical practice

The ESPEN guidelines suggest considering a repletion dose of 50–100 mg pyridoxine in patients with chronic poor intake in addition to the recommended daily dose of 1.5 mg per day in enteral nutrition and 4–6 mg per day in PN. High‐dose pyridoxine may be needed in isoniazid overdose: 1 g of pyridoxine for each gram of isoniazid ingested with a maximum of 5 g. There is no evidence of beneficial effects of high‐dose pyridoxine, and symptoms of toxicity may be observed with dosages > 500 mg/day.

Folate

Main form and functions

Folate, a water‐soluble vitamin also known as vitamin B 9, is the generic term for a family of compounds including folic acid and its derivatives (5‐methyltetrahydrofolate, 5‐formyltetrahydrofolate or folinic acid, 10‐formyltetrahydrofolate and 5,10‐methylenetetrahydrofolate). Folate has essential cellular functions as a coenzyme in single‐carbon transfers in the synthesis of DNA and RNA and amino acid metabolism.

---

### Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV [^113futbT]. HIV.gov (2025). High credibility.

For drug-susceptible tuberculosis (TB) in people with HIV, preferred therapy includes defined intensive and continuation phases with specified durations. Intensive Phase (8 weeks): Isoniazid plus (rifampin or rifabutin) plus pyrazinamide plus ethambutol plus pyridoxine 25–50 mg PO daily (AI). If molecular or phenotypic drug susceptibility reports show sensitivity to isoniazid and rifampin, then ethambutol may be discontinued before the end of 8 weeks (AI). Continuation Phase (for Drug-Susceptible TB): Isoniazid plus (rifampin or rifabutin) plus pyridoxine 25–50 mg PO daily (AII). Total Duration of Therapy: Pulmonary, drug-susceptible, uncomplicated TB: 6 months (BII); Pulmonary TB and positive culture at 8 weeks of TB treatment, severe cavitary disease or disseminated extrapulmonary TB: 9 months (BII); Extrapulmonary TB with TB meningitis: 9–12 months (BII); Extrapulmonary TB in other sites: 6 months (BII).

---

### Ascorbic acid, vitamin a palmitate, cholecalciferol, thiamine hydrochloride, riboflavin-5 phosphate sodium, pyridoxine hydrochloride, niacinamide, dexpanthenol, α-tocopherol acetate, vitamin k1, folic acid, biotin, cyanocobalamin (adult infuvite multiple vitamins) [^114aRpn5]. FDA (2025). Medium credibility.

7 DRUG INTERACTIONS

A number of interactions between vitamins and drugs have been reported. The following are examples of these types of interactions:

Effect of INFUVITE ADULT on other drugs:

Antibiotics: Thiamine, riboflavin, pyridoxine, niacinamide, and ascorbic acid decrease activities of erythromycin, kanamycin, streptomycin, doxycycline, and lincomycin (7.1)
Bleomycin: Ascorbic acid and riboflavin may reduce the activity of bleomycin (7.1)
Levodopa: Pyridoxine may decrease blood levels of levodopa and levodopa efficacy may decrease (7.1)
Phenytoin: Folic acid may decrease phenytoin blood levels and increase risk of seizure activity (7.1)
Methotrexate: Folic acid may decrease response to methotrexate (7.1)

Effects of other drugs on INFUVITE ADULT:

Hydralazine, Isoniazid: Concomitant administration of hydralazine or isoniazid may increase pyridoxine requirements (7.2).
Phenytoin: May decrease folic acid concentrations (7.2)
Chloramphenicol: In patients with pernicious anemia, the hematologic response to vitamin B12 therapy may be inhibited (7.2)

7.1 Drug Interactions Affecting Co-administered Drugs

Warfarin: Vitamin K, a component of INFUVITE ADULT, antagonizes the anticoagulant action of warfarin. In patients who are co-administered warfarin and INFUVITE ADULT, blood levels of prothrombin/INR should be monitored to determine if dose of warfarin needs to be adjusted [see Warnings and Precautions (5.4)].

Antibiotics: Thiamine, riboflavin, pyridoxine, niacinamide, and ascorbic acid decrease antibiotic activities of erythromycin, kanamycin, streptomycin, doxycycline, and lincomycin.

Bleomycin: Ascorbic acid and riboflavin inactivate bleomycin in vitro, thus the activity of bleomycin may be reduced.

Levodopa: Pyridoxine may increase the metabolism of levodopa (decrease blood levels of levodopa) and decrease its efficacy.

Phenytoin: Folic acid may increase phenytoin metabolism and lower the serum concentration of phenytoin resulting in increased seizure activity.

Methotrexate: Folic acid may decrease a patient's response to methotrexate therapy.

7.2 Drug Interactions Affecting Vitamin Levels

Hydralazine, Isoniazid: Concomitant administration of hydralazine or isoniazid may increase pyridoxine requirements.

Phenytoin: Phenytoin may decrease serum folic acid concentrations.

Chloramphenicol: In patients with pernicious anemia, the hematologic response to vitamin B12 therapy may be inhibited by chloramphenicol.

---

### Use of pyridoxine hydrochloride to prevent isoniazid toxicity… [^114nV4PM]. JAMA Network (2025). Excellent credibility.

There have been several recent reports1 regarding the ability of pyridoxine hydrochloride and its derivatives, pyridoxal and pyridoxamine, to prevent or to delay the appearance of peripheral neuritis due to isoniazid administration. This finding was followed by the suggestion that it is now possible to use much larger doses of isoniazid than have been used routinely heretofore. Subsequently, Pope2 has shown that pyridoxal and pyridoxamine can interfere with the tuberculostatic action of isoniazid in vitro, and McCune3 has shown an in vivo interference with isoniazid by pyridoxine. The present study was undertaken to confirm or to deny the earlier reports that the toxic effects resulting from large doses of isoniazid could be prevented by the concomitant administration of pyridoxine. Methods and Results Forty-eight patients were given isoniazid in the Ross RR.

USE OF PYRIDOXINE HYDROCHLORIDE TO PREVENT ISONIAZID TOXICITY. JAMA. 1958; 168: 273–275.

---

### A systematic review and meta-analysis of isoniazid pharmacokinetics in healthy volunteers and patients with tuberculosis [^116EHNkG]. Clinical Therapeutics (2020). Medium credibility.

Purpose

This systematic review and meta-analysis assesses the pharmacokinetic (PK) summary estimates of isoniazid (INH) between healthy volunteers and patients with tuberculosis (TB), evaluates whether the current INH dose regimen is appropriate in patients with TB, and evaluates the impact of N-acetyl-transferase-2 (NAT2) status on the PK properties of INH.

Methods

A systematic approach was conducted to find studies with relevant INH PK data published in the English language up to February 2018. The PK properties of INH were extracted with their respective INH dosages and were dose normalized to allow a fair comparison between healthy volunteers and patients with TB. Meta-analysis was then performed for the C max and AUC estimates for all INH dosages.

Findings

Ninety studies were included in this systematic review. TB status significantly affected the INH C max and AUC estimates. In healthy volunteers, the dose-normalized INH C max and AUC were statistically higher than those of patients with TB. No significant differences were found in dose-normalized C max and AUC between adults with TB and adults with TB/HIV; however, the AUC in pediatric patients was significantly different between patients with TB and patients with TB/HIV. In addition, no significance was observed comparing the dose-normalized C max and AUC of pediatric patients with TB and TB/HIV with their respective adult counterparts. Dose-normalized INH C max and AUC in patients with fast and intermediate NAT2 were significantly lower than in patients with slow NAT2.

Implications

The current recommended dosages of INH were found to produce less drug exposure in patients with TB when compared with healthy volunteers. NAT2 polymorphism greatly impacts the PK properties of INH; hence, testing for acetylator status is highly recommended, and therapeutic drug monitoring would help reduce INH toxicity.

---

### Isoniazid-associated pellagra during mass scale-up of tuberculosis preventive therapy: a case-control study [^113gYxvd]. The Lancet: Global Health (2022). High credibility.

People with isoniazid-associated pellagra, although a rare condition, benefited from simple interventions, including prompt discontinuation of isoniazid and completion of a 30-day course of multi-B vitamins. Isoniazid retains a critical, lifesaving role in preventing and treating tuberculosis. As with other potential adverse effects, a risk of pellagra ought not to preclude people living with HIV from the benefits of isoniazid in tuberculosis prevention. Rather, programmes might wish to enhance patient education and pharmaco-vigilance. Currently, some national guidelines call for the co-administration of vitamin B6, a cofactor in the kynurenine pathway, with IPT to prevent neuropathy. Co-administration of vitamin B6 showed a modest protective effect in this study. Niacin-containing multi-B vitamin co-administration with isoniazid as pellagra prevention is worth exploring. Finally, addressing structural inequities and implementing innovative population-level fortification strategies in under-nourished populations remain urgent, still unfulfilled public health solutions. In their absence, targeted food supplementation and fortification efforts for people living with HIV starting isoniazid-containing regimens, particularly people living with HIV facing food insecurity and lactating women, might prevent pellagra.

---

### Managing advanced HIV disease in a public health approach [^111BtTjp]. Clinical Infectious Diseases (2018). Low credibility.

The second trial (REALITY) enrolled 1805 participants (mainly adults) living with HIV with CD4 counts < 100 cells/µL (median CD4 count was 36 cells/µL and half were classified as WHO clinical stage 1 or 2) from Kenya, Malawi, Uganda, and Zimbabwe. Trial participants were randomized to the standard of care (cotrimoxazole) according to national guidelines or an enhanced prophylaxis package (12 weeks of fluconazole [100 mg once daily], 12 weeks of a fixed-dose combination of cotrimoxazole [800 + 160 mg] + isoniazid [300 mg] + pyridoxine [25 mg] as a scored once-daily tablet, 5 days of 500 mg of azithromycin once daily, and a single dose of 400 mg of albendazole). The doses were halved for children 5–12 years old (except for albendazole). All drugs were started simultaneously in the absence of any blood tests, and ART was offered on the same day as the prophylaxis package. Isoniazid + pyridoxine use beyond 12 weeks followed national guidelines. Participants already receiving or needing antimicrobial treatment or prophylaxis pragmatically received it outside the randomized design, and received other prophylaxis according to randomization. Patients who had started the enhanced-prophylaxis package at the time of ART initiation had a 27% lower rate of death than those who received standard prophylaxis with cotrimoxazole alone (8.9% vs 12.2%; hazard ratio, 0.73 [95% CI,.55–.98]; p = 0.03). Incidence of TB was significantly lower with enhanced prophylaxis than with standard prophylaxis (7.1% vs 10.2%. respectively), as was the incidence of cryptococcal disease (1.0% vs 2.6%), candidiasis (1.1% vs 2.6%), and new hospitalization (17.0% vs 20.7%). In the main trial report, it was concluded that the REALITY package would fall within cost-effectiveness thresholds for low-income countries. More extensive costing analyses are under way.

---

### Tuberculosis preventive treatment: the next chapter of tuberculosis elimination in India [^111n2Aqf]. BMJ Global Health (2018). Medium credibility.

Challenge 4 — Tuberculosis preventive treatment acceptance, adherence and completion

The initiation and adherence to TPT has been historically poor. This may be a result of lack of general awareness and perceived risk, non-availability of standard tuberculin product, drug stock-outs (including pyridoxine), limited access to radiography (to exclude TB disease), long duration of therapy (in absence of symptoms) and poor programmatic monitoring. Moreover, in India, the practice of TPT is predominately for children. In the few studies that enrolled adult participants, TPT acceptance rates were exceptionally low (17%)or treatment was not offered because of perceived high background tuberculosis infection prevalence, risk of repeated exposure and reinfection, risk of drug toxicity and concerns of widespread isoniazid monoresistance in India. All of these concerns are relevant. The risk of drug intolerance and severe toxicity, although worrisome, were infrequent in other settings, and appear to be age-associated, or found among persons with other risk factors for hepatotoxicity (eg, excessive alcohol use). In some high-prevalence TB settings, where the risk of reinfection is high, studies have demonstrated benefit of preventive treatment with longer durations. A study from Chennai found that both 6-month and 36-month isoniazid preventive treatment regimens among HIV-infected persons was equivalent in safety, tolerance and effectiveness. The optimal length of TPT in India remains unknown (eg, extended duration regimens to cover reinfection vs shorter adherence-friendly regimens) and is likely subject to feasibility and other logistical considerations. High rates of treatment completion (87%) were recently reported in routine practice using a 12-dose weekly isoniazid and rifapentine regimen (3HP) in a low-prevalence country. This treatment holds promise to improve acceptance and adherence to TPT worldwide; however, the efficacy of 3HP among populations with a high prevalence of drug resistance remains unknown. Indeed, drug resistance in India is also a concern. The recent nationally representative antituberculosis drug resistance survey found that 11% of new and 25% previously treated patients had a form of isoniazid-resistant tuberculosis. These results, when extrapolated to estimated number of new household contacts with tuberculosis infection, suggest that millions of persons every year may not benefit from the various regimens designed to halt the progression from infection to active forms of drug-resistant tuberculosis (table 1). Unfortunately, there is no diagnostic test that can assess the drug susceptibility profile of any given infection (non-active TB), and there are no published randomised clinical trials for the treatment of tuberculosis infection caused by isoniazid-resistant or multidrug-resistant (MDR) forms of tuberculosis. However, several alternative preventive regimens are available. Contacts of patients with isoniazid-monoresistant TB have been successfully treated with rifampicin-based regimensand support the current recommendations to use 4 months of daily rifampicin under certain conditions. Among MDR TB contacts, fluoroquinolone-based preventive treatment may be considered, global treatment guidelines are forthcoming, but further research is needed prior to wide-scale use, — especially in India where overconsumptionand uncontrolled use of fluoroquinolones has been reported. It is unclear which TPT regimen would be most effective in India. We must establish which TPT regimens are most effective in India, with careful consideration of posology and duration for children and adults. Notwithstanding, all persons offered TPT must be thoroughly evaluated to rule out active disease, assessed to select an appropriate treatment course (including careful review of potential exclusion conditions) and closely monitored for the development of treatment-related adverse events and poor adherence.

---

### Isoniazid-induced gynaecomastia: report of a paediatric case and review of literature [^1129GZXu]. BMC Endocrine Disorders (2020). Medium credibility.

In our patient, clinical examination and laboratory studies showed no evidence of liver, renal or thyroid disorder. Tumour markers were also taken to rule out the possibility of a HCG-producing tumour which may cause stimulation of Leydig cells. He was not obese and did not have excessive weight gain during the course of treatment, making obesity and refeeding gynaecomastia less likely. His gonadotrophins were within the pre-pubertal range while estradial was mildly elevated for his age and sex.

Isoniazid is known to induce pyridoxine (vitamin B6) deficiency by inhibitng pyridoxal phosphokinase and by combining with pyridoxine to form isonicotinylhydrazide which is excreted in urine. Apart from causing the well-known side effect of peripheral neuropathy, isoniazid was also postulated to cause altered estrogen-androgen metabolism. The physiologically active form of vitamin B6, pyridoxal 5-phosphate (PLP), acts as a modulator of steroid hormone receptor- mediated gene expression. Elevation of intracellular PLP leads to a decreased transcriptional response to glucocorticoid hormones, progesterone, androgens, and estrogens, while cells in a vitamin B6-deficient state exhibit enhanced responsiveness to steroid hormone. This might thus account for the elevated estradial level in our patient. Another possible mechanism is "refeeding gynaecomastia" associated with weight gain during anti-tuberculosis therapy, but this was not seen in our case.

We performed a literature search in Pubmed and Medline using text terms "isoniazid" and "gyneacomastia". Animal studies and articles written in a language other than English were excluded. Ten articles describing such phenomenon in adult patients were found (Table 1). Age of presentation ranges from 18 to 72 years old, with mean age of 40.9 years old. Gynaecomastia occurred 3–6 months (mean 4.5 months) after isoniazid treatment, and subsided at variable time frame ranging from 1 month to 1 year. Bilateral breasts were involved in 60% (n = 6) of the cases. Our reported case is the youngest among all and is the only reported pre-pubertal case. Like most of the reported cases, there was bilateral involvement of the breasts. The clinical course of our patient resembles the reported adult cases, with gynaecomastia occurring 4 months after isoniazid intake. Breast enlargement resolved 8 weeks upon cessation of medication in our case. The relatively quick resolution might be related to the absence of pre-existing breast tissue in pre-pubertal males.

---

### Guidelines for the prevention and treatment of opportunistic infections in children with and exposed to HIV [^1155m9eE]. HIV.gov (2025). High credibility.

Children with HIV taking isoniazid or cycloserine — pyridoxine supplementation (1–2 mg/kg body weight/day, maximum 50 mg/day) is recommended for all children with HIV who are taking isoniazid or cycloserine (expert opinion).

---

### Case report: isoniazid-associated delirium in an elderly female with spinal tuberculosis [^111pcvaA]. The American Journal of Tropical Medicine and Hygiene (2022). Medium credibility.

Isoniazid is an important component of first-line antitubercular therapy. The drug at its therapeutic dose is known to cause hepatitis and peripheral neuropathy. The association of isoniazid with pure delirium is rare. Here, we present an interesting case of new-onset delirium associated with isoniazid in an elderly female with spinal tuberculosis. Remarkable improvement was noticed in the patient following drug discontinuation and pyridoxine augmentation.

---

### The 3 HP regimen for tuberculosis preventive treatment: safety, dosage and related concerns during its large-scale implementation in countries like India [^114pRCGn]. The Lancet Regional Health: Southeast Asia (2024). High credibility.

The recommended standard daily dose of isoniazid for INH-susceptible tuberculosis or the daily isoniazid preventive treatment is 5 mg/kg in adults and 10–15 mg/kg in children. In case of the once-weekly isoniazid for either indication the maximum recommended dose is 15 mg/kg. In the case of drug-resistant tuberculosis where high dose-isoniazid (designated as Hh) was used earlier as a companion drug, the recommended doses were 10–15 mg/kg in adults and 15–20 mg/kg in children. So the highest recommended dose of INH recommended for either daily dosing in drug-resistant TB or weekly dosing in drug-susceptible TB or TB infection is 15 mg/kg. This translates into maximum doses of 450–600 mg across the lowest or the highest weight bands.

Table 2 shows doses of isoniazid in different indications and in extremes of weight bands (30–35 kg in lower range and > 70 kg in higher range). These range from 225 to 375 mg daily for drug-susceptible treatment, 450–600 mg daily in high-dose isoniazid treatment for drug-resistant TB, and a fixed dose of 900 mg weekly isoniazid recommended by WHO in the 3 HP regimen. age > 14 years. This dose of 900 mg is higher than the maximum recommended weight-based dose (15 mg/kg) for any subject weighing < 60 kg. In the weight band of 30–45 kg subjects, this fixed dose would translate into a weight-based dose of 20–30 mg/kg, approaching the toxic dose of 30 kg. There are reports of isoniazid causing neurological syndromes as a part of toxicity that varies with doses 2% at the dose of 5 mg/kg to about 15% at 10 mg/kg, which is dose related with toxicity that may include peripheral neuropathy, dizziness, dysarthria, confusion and even seizures. Seizures have been documented in a recipient of the 3 HP, who was an immunocompetent adult without malnutrition, and was attributed to the INH component.

---

### PYRIDOXINE HCI INJECTION, USP 100mg per mL 1mL VIAL… [^113iPcka]. FDA (DailyMed) (2024). Medium credibility.

PYRIDOXINE HCI- pyridoxine hci injection, solution HF Acquisition Co LLC, DBA HealthFirst ----------. The need for pyridoxine increases with the amount of protein in the diet. The tryptophan load test appears to uncover early vitamin B6 deficiency by detecting xanthinurea. The average adult minimum daily requirement is about 1. 25 mg. The "Recommended Dietary Allowance" of the National Academy of Sciences is estimated to be as much as 2. 2 mg for adults and
2. 5 mg for pregnant and lactating women. The requirements are more in persons having certain genetic defects or those being treated with isonicotinic acid hydrazide or oral contraceptives. Pyridoxine Hydrochloride Injection is effective for the treatment of pyridoxine deficiency as seen in the following: Inadequate dietary intake. Drug-induced deficiency, as from isoniazid or oral contraceptives. Inborn errors of metabolism, e.g., vitamin B6 dependent convulsions or vitamin B6 responsive anemia.

Symptoms of dependence have been noted in adults given only 200 mg daily, followed by withdrawal. Pyridoxine given to animals in amounts of 3 to 4 g/kg of body weight produces convulsions and death. In man, a dose of 25 mg/kg of body weight is well tolerated. Pyridoxine Hydrochloride Injection may be administered intramuscularly or intravenously. In cases of dietary deficiency, the dosage is 10 to 20 mg daily for 3 weeks. Follow-up treatment is recommended daily for several weeks with an oral therapeutic multivitamin preparation containing 2 to 5 mg pyridoxine. Poor dietary habits should be corrected, and an adequate, well balanced diet should be prescribed. The vitamin B6 dependency syndrome may require a therapeutic dosage of as much as 600 mg a day and a daily intake of 30 mg for life. In deficiencies due to INH, the dosage is 100 mg daily for 3 weeks followed by a 30 mg maintenance dose daily.

In poisoning caused by ingestion of more than 10 g of INH, an equal amount of pyridoxine should be given — 4 g intravenously followed by 1 g intramuscularly every 30 minutes.

---

### Isoniazid-induced status epilepticus in a pediatric patient after inadequate pyridoxine therapy [^1168UGE5]. Pediatric Emergency Care (2010). Low credibility.

Background

Isoniazid (INH) is an effective treatment for tuberculosis and among the most common causes of drug-induced seizures in the United States. Isoniazid intoxication produces a characteristic clinical syndrome including seizures, metabolic acidosis, and, in severe cases, respiratory depression and coma.

Case

A 10-month-old male infant was presented after being found with his father's INH. The patient was brought to a local hospital where he had a witnessed generalized seizure and was given 650 mg pyridoxine intravenously, which was based on a 70 mg/kg recommendation. Five hours after the time of ingestion, the patient developed recurrent generalized seizures. He was given diazepam and then loaded with phenobarbital 20 mg/kg, while awaiting more pyridoxine from the pharmacy. He received an additional 2 g pyridoxine for a suspected ingestion of approximately 2.7 g INH (290 mg/kg total dose), and his seizures subsequently resolved.

Discussion

Treatment of INH toxicity must address correction of gamma-aminobutyric acid deficiency with pyridoxine replacement and management of life-threatening events. For poisonings in which the amount of INH ingested is known, pyridoxine is dosed on a gram-for-gram basis. Several reference textbooks recommend pyridoxine dosing in children to be 70 mg/kg. This was the justification for the initial pyridoxine dose administered in our case. However, after review of the referenced literature, the rationale supporting this recommendation remains unclear. Benzodiazepines should also be given with pyridoxine as they have been shown to have a synergistic effect in terminating seizures in animal models.

Conclusions

As soon as possible after INH overdose is suspected or diagnosed, pyridoxine should be administered in a dose approximately equal to the estimated amount of INH ingested regardless of the age of the patient.

---

### Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV [^116LLnYh]. HIV.gov (2025). High credibility.

Isoniazid alternative regimen for LTBI: Isoniazid 300 mg PO daily plus pyridoxine 25 mg to 50 mg PO daily for 6 to 9 months is an alternative regimen for the treatment of LTBI (AII). Daily isoniazid for 6 to 9 months is effective and reasonably well-tolerated; severe toxicity is infrequent, but longer courses of isoniazid (e.g., 12 months) are more effective at preventing TB but carry a higher risk of toxicity and patients are more likely to complete shorter regimens. When isoniazid is used, it should be supplemented with pyridoxine at a dose of 25 to 50 mg per day to prevent peripheral neuropathy (AIII).

---

### Pyridoxine hci [^115q2raZ]. FDA (2024). Medium credibility.

INDICATIONS & USAGE

Pyridoxine Hydrochloride Injection is effective for the treatment of pyridoxine deficiency as seen in the following:

Inadequate dietary intake.

Drug-induced deficiency, as from isoniazid (INH) or oral contraceptives.

Inborn errors of metabolism, e.g., vitamin B6 dependent convulsions or vitamin B6 responsive anemia.

The parenteral route is indicated when oral administration is not feasible as in anorexia, nausea and vomiting, and preoperative and postoperative conditions. It is also indicated when gastrointestinal absorption is impaired.

---

### Impact of the increased recommended dosage of isoniazid on pyridoxine levels in children and adolescents [^111Yu73r]. The Pediatric Infectious Disease Journal (2016). Low credibility.

Isoniazid exposure causes dose-dependent pyridoxine deficiency. Recently, the recommended dosage of isoniazid in children was increased from 5 (4–6) to 10 (10–15) mg/kg/day. We aimed to analyze longitudinally pyridoxine levels in a cohort of previously healthy children and adolescents treated with isoniazid. Mild symptom-free pyridoxine deficiency was observed in 4/75 (5.6%) and 3/40 (7.5%) at baseline and at 3-month follow-up, respectively. Classical age-related risk factors identified patients at risk of pyridoxine deficiency. Our preliminary results support current recommendations regarding pyridoxine supplementation in healthy children.

---

### New approaches in the diagnosis and treatment of latent tuberculosis infection [^113nwG8x]. Respiratory Research (2010). Low credibility.

Table 2
Currently available drug regimens for the treatment of latent tuberculosis infection

INH, isoniazid; RMP, rifampicin; PZA, pyrazinamide; RPE, rifapentine; DOT, directly observed treatment; 2/Wk, twice weekly; 1/Wk, once weekly; CDC, Center for Disease Control and Prevention; HIV, human immunodeficiency virus; IUAT, international Union Against Tuberculosis; LTBI, latent tuberculosis infection

The standard regimen for the treatment of LTBI in United States and Canada is daily self-administered therapy with isoniazid (INH) for nine months based on clinical trial data but the duration of treatment can be reduced to 6 months for adults seronegative for HIV-infection. The International Union Against Tuberculosis (IUAT) recommends daily therapy with INH for 12 months as it is more effective than the 6-month course (75% vs. 65%). The preferred duration of treatment for most patients with LTBI in the United States and European countries is 9 months since clinical trial data showed that the efficacy of 6-month regimen is reduced to 60% while 12-month regimen is advocated for individuals at higher risk of developing active disease. According to the CDC guidelines, the frequency can also be reduced from daily therapy to twice weekly therapy with increased dosage of INH, however, the twice weekly regimen must be given as directly observed treatment (DOT). Inclusion of DOT adds a substantial additional expense to the treatment strategies. The efficacy of INH treatment in preventing active TB exceeds 90% among persons who complete treatment. However, the overall effectiveness of these regimens is severely limited as the completion rates in clinical settings have been rather low, ranging from 30% to 64% only. Completion rates in other settings have been even lower. Although INH is tolerated fairly well by most of the individuals, there is a risk of hepatic toxicity in selected populations. Studies have shown that 10% to 22% of participants taking INH for LTBI have at least one episode of elevated serum transaminase levels. Although the rates of clinically significant hepatitis were much lower (< 2%), the risk and severity increased with age and concomitant alcohol consumption. INH can also cause peripheral neuropathy but the risk can be lowered by concomitant use of pyridoxine (vitamin B6). Poor adherence due to the long duration of treatment and concerns for hepatotoxicity in selected patient populations resulted in development of shorter and more effective treatment options for LTBI.

---

### The 3 HP regimen for tuberculosis preventive treatment: safety, dosage and related concerns during its large-scale implementation in countries like India [^112YYVDJ]. The Lancet Regional Health: Southeast Asia (2024). High credibility.

The 3-month once-weekly isoniazid-rifapentine (3 HP) regimen for tuberculosis preventive treatment recommended by WHO is being rolled in countries including India. It has higher completion rates and lower risk of hepatotoxicity than isoniazid preventive treatment, but trials also showed higher frequency of systemic drug reactions (SDRs) including flu-like syndromes and dizziness, and also uncommon Grade 3 or 4 adverse events like hypotension, syncope, bronchospasm. Low BMI is a risk factor for SDRs. Available data on safety of 3 HP in the Asian region is limited, heterogeneous, but points to a higher frequency of SDRs suggesting a need for caution in its large-scale implementation. 19% (118/614) of household contacts initiated on 3 HP in Delhi reported dizziness. Multiple lines of evidence including pharmacokinetic data suggest that the SDRs may be related to isoniazid and its plasma concentration. WHO and national guidelines for the 3 HP regimen currently recommend a fixed dose of once-weekly 900 mg isoniazid in adults regardless of body weight that poses a risk of SDRs for lower weight adults, amplified by the acetylator status and the lack of co-administration of pyridoxine. Weight based dosing, co-administration of pyridoxine and pharmacovigilance studies should accompany the roll out of 3 HP to ensure its safe and successful implementation.

---

### Isoniazid [^11172MYV]. FDA (2025). Medium credibility.

Signs and Symptoms

Isoniazid overdosage produces signs and symptoms within 30 minutes to 3 hours after ingestion. Nausea, vomiting, dizziness, slurring of speech, blurring of vision and visual hallucinations (including bright colors and strange designs) are among the early manifestations. With marked overdosage, respiratory distress and CNS depression, progressing rapidly from stupor to profound coma, are to be expected, along with severe, intractable seizures. Severe metabolic acidosis, acetonuria and hyperglycemia are typical laboratory findings.

Treatment

Untreated or inadequately treated cases of gross isoniazid overdosage, 80 mg/kg to 150 mg/kg, can cause neurotoxicity6 and terminate fatally, but good response has been reported in most patients brought under adequate treatment within the first few hours after drug ingestion.

For the Asymptomatic Patient

Absorption of drugs from the GI tract may be decreased by giving activated charcoal. Gastric emptying should also be employed in the asymptomatic patient. Safeguard the patient's airway when employing these procedures. Patients who acutely ingest greater than 80 mg/kg should be treated with intravenous pyridoxine on a gram per gram basis equal to the isoniazid dose. If an unknown amount of isoniazid is ingested, consider an initial dose of 5 grams of pyridoxine given over 30 to 60 minutes in adults or 80 mg/kg of pyridoxine in children.

For the Symptomatic Patient

Ensure adequate ventilation, support cardiac output and protect the airway while treating seizures and attempting to limit absorption. If the dose of isoniazid is known, the patient should be treated initially with a slow intravenous bolus of pyridoxine, over 3 to 5 minutes, on a gram per gram basis, equal to the isoniazid dose. If the quantity of isoniazid ingestion is unknown, then consider an initial intravenous bolus of pyridoxine of 5 grams in the adult or 80 mg/kg in the child. If seizures continue, the dosage of pyridoxine may be repeated. It would be rare that more than 10 grams of pyridoxine would need to be given. The maximum safe dose for pyridoxine in isoniazid intoxication is not known. If the patient does not respond to pyridoxine, diazepam may be administered. Phenytoin should be used cautiously, because isoniazid interferes with the metabolism of phenytoin.

General

Obtain blood samples for immediate determination of gases, electrolytes, BUN, glucose, etc.; type and cross-match blood in preparation for possible hemodialysis.

---

### Guidelines for the prevention and treatment of opportunistic infections among HIV-exposed and HIV-infected children: recommendations from CDC, the National Institutes of Health, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics [^112naEmG]. MMWR: Recommendations and Reports (2009). Medium credibility.

Mycobacterium tuberculosis (post-exposure) primary prophylaxis in HIV-exposed and HIV-infected children lists as first choice for a source case drug susceptible isoniazid 10–15 mg/kg body weight (maximum 300 mg/day) by mouth daily for 9 months, and for a source case drug resistant it states to consult expert and local public health authorities. Alternatives include: if adherence with daily isoniazid cannot be ensured, consider isoniazid 20–30 mg/kg body weight (maximum 900 mg/ day) by mouth 2 times a week by DOT for 9 months; isoniazid 10–15 mg/kg body weight (maximum 300 mg/ day) and rifampin 10–20 mg/kg body weight (maximum 600 mg/day) by mouth daily for 3–4 months; or rifampin 10–20 mg/kg body weight (maximum 600 mg/ day) by mouth daily for 4–6 months. Drug-drug interactions with cART should be considered for all rifamycin containing alternatives. Indication includes positive TST (TST ≥ 5 mm) or IGRA without previous TB treatment, close contact with any infectious TB case (repeated exposures warrant repeated post-exposure prophylaxis), and TB disease must be excluded before starting treatment; there is no indication for pre-exposure and post-treatment prophylaxis. Criteria for discontinuing prophylaxis specify only with documented severe adverse event, which is exceedingly rare. Adjunctive treatment is pyridoxine 1–2 mg/kg body weight once daily (maximum 25–50 mg/day) with isoniazid; pyridoxine supplementation is recommended for exclusively breastfed infants and for children and adolescents on meat- and milk-deficient diets; children with nutritional deficiencies, including all symptomatic HIV-infected children; and pregnant adolescents and women.

---

### Updates on the treatment of drug-susceptible and drug-resistant tuberculosis: an official ATS / CDC / ERS / IDSA clinical practice guideline [^115xM1wx]. American Journal of Respiratory and Critical Care Medicine (2025). High credibility.

Regarding medical management for pulmonary tuberculosis, more specifically with respect to management of drug-susceptible tuberculosis, ATS/CDC/ERS/IDSA 2025 guidelines recommend to consider administering a 4-month regimen composed of isoniazid, rifapentine, moxifloxacin, and pyrazinamide in patients aged ≥ 12 years with drug-susceptible pulmonary tuberculosis:

| **Situation** | **Guidance** |
|-|-|
|Isoniazid|- 300 mg PO daily for 17 weeks|
|Rifapentine|- 1,200 mg PO daily for 17 weeks|
|Pyrazinamide|- Weight-based dosing daily for 8 weeks <br/> - 1,000 mg PO daily for 40–55 kg <br/> - 1,500 mg PO daily for > 55–75 kg <br/> - 2,000 mg PO daily for > 75 kg|
|Moxifloxacin|- 400 mg PO daily for 17 weeks.|

---

### Isoniazid [^113Lxoj7]. FDA. Low credibility.

The dosage of isoniazid PO for prevention of tuberculosis in adults is 300 mg PO daily

---

### Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America [^112dBfcz]. MMWR: Recommendations and Reports (2009). Medium credibility.

Treating latent tuberculosis infection (LTBI) to prevent TB disease — indications include a positive screening test for LTBI with no evidence of active TB disease and no prior history of treatment for active disease or LTBI, and close contact with a person with infectious TB regardless of screening test result. Preferred therapy is isoniazid 300 mg by mouth (PO) daily plus pyridoxine 25–50 mg PO daily (AI) for 9 months. Alternative therapies include once-weekly rifapentine plus isoniazid 15 mg/kg PO with pyridoxine 50 mg PO for 12 weeks with a 900 mg maximum rifapentine dose and weight-based doses of 750 mg for those weighing 32.1–49.9 kg and 900 mg for those weighing ≥ 50.0 kg; note that rifapentine is only recommended for patients receiving an efavirenz- or raltegravir-based antiretroviral therapy (ART) regimen. Another alternative is rifampin 600 mg PO daily for 4 months (BI). For persons exposed to drug-resistant TB, select anti-TB drugs after consultation with experts or with public health authorities.

---

### Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV [^114m1E8g]. HIV.gov (2025). High credibility.

Preferred regimen 3HP for latent tuberculosis infection (LTBI) in people with HIV — rifapentine (weight-based dosing) orally (PO) once weekly plus isoniazid 15 mg/kg PO once weekly (900 mg maximum) plus pyridoxine 50 mg PO once weekly for 12 weeks is one of two preferred regimens for the treatment of LTBI (AI). In two randomized controlled trials, rifapentine plus isoniazid once weekly for 12 weeks (3HP) was as effective and well-tolerated as 6 to 9 months of daily isoniazid, including in people with HIV whose CD4 counts were generally > 350 cells/mm³ and who were not yet on ART. 3HP treatment completion rates with self-administered therapy were inferior to those with directly observed therapy (DOT) but non-inferior among study participants enrolled in the United States — and generally high overall.

---

### Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America [^111XEfQP]. MMWR: Recommendations and Reports (2009). Medium credibility.

Mycobacterium tuberculosis infection (i.e., latent TB infection [LTBI]) prophylaxis — adults and adolescents with HIV: Indications include "Positive screening test for LTBI, b with no evidence of active TB, and no prior treatment for active TB or LTBI (AI)" or "Close contact with a person with infectious TB, with no evidence of active TB, regardless of screening test results (AI)". Preferred therapy is "(INH 300 mg plus pyridoxine 25–50 mg) PO daily for 9 months (AII)". The guideline notes, "LTBI treatment and ART act independently to decrease the risk of TB disease. Thus, ART is recommended for all persons with HIV and LTBI (AI)". Alternatives are "Rifapentine (see dose below) PO plus INH 900 mg PO plus pyridoxine 50 mg PO once weekly for 12 weeks (AII)" with "Rifapentine Weekly Dose Weighing 32.1 to 49.9 kg:

- **750 mg Weighing > 50 kg**:

- 900 mg", "Rifampin 600 mg PO daily for 4 months (BI)", and "For persons exposed to drug-resistant TB, select anti-TB drugs after consultation with experts or public health authorities (AII)". Note that "Rifapentine only recommended for persons receiving RAL or EFV-based ART regimen".

---

### Rifapentine (Priftin) [^112e3AjZ]. FDA (2025). Medium credibility.

6	ADVERSE REACTIONS

The following serious and otherwise important adverse drug reactions are discussed in greater detail in other sections of labeling:

Hepatotoxicity [see Warnings and Precautions (5.1)]
Hypersensitivity [see Contraindications (4.1) and Warnings and Precautions (5.2)]
Severe Cutaneous Adverse Reactions [see Warnings and Precautions (5.3)]
Discoloration of Body Fluids [see Warnings and Precautions (5.6)]
Clostridioides Difficile –Associated Diarrhea [see Warnings and Precautions (5.7)]
Porphyria [see Warnings and Precautions (5.8)]

6.1	Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Active Pulmonary Tuberculosis

PRIFTIN was studied in a randomized, open label, active-controlled trial of HIV-negative patients with active pulmonary tuberculosis. The population consisted primarily of male subjects with a mean age of 37 ± 11 years. In the initial 2-month phase of treatment, 361 patients received PRIFTIN 600 mg twice a week in combination with daily isoniazid, pyrazinamide, and ethambutol and 361 subjects received rifampin in combination with isoniazid, pyrazinamide and ethambutol all administered daily. Ethambutol was discontinued when drug susceptibly testing was known. During the 4-month continuation phase, 317 patients in the PRIFTIN group continued to receive PRIFTIN 600 mg dosed once weekly with isoniazid and 304 patients in the rifampin group received twice weekly rifampin and isoniazid. Both treatment groups received pyridoxine (Vitamin B6) over the 6-month treatment period.

Because PRIFTIN was administered as part of a combination regimen, the adverse reaction profile reflects the entire regimen.

Twenty-two deaths occurred in the study, eleven in the rifampin combination therapy group and eleven in the PRIFTIN combination therapy group. 18/361 (5%) rifampin combination therapy patients discontinued the study due to an adverse reaction compared to 11/361 (3%) PRIFTIN combination therapy patients. Three patients (two rifampin combination therapy patients and one PRIFTIN combination therapy patient) were discontinued in the initial phase due to hepatotoxicity. Concomitant medications for all three patients included isoniazid, pyrazinamide, ethambutol, and pyridoxine. All three recovered without sequelae.

---

### The 3 HP regimen for tuberculosis preventive treatment: safety, dosage and related concerns during its large-scale implementation in countries like India [^116y7zAn]. The Lancet Regional Health: Southeast Asia (2024). High credibility.

Introduction

Tuberculosis preventive treatment (TPT) is an important component of the global END TB strategy. Recently, the WHO recommended shorter rifamycin based regimens; 3 months of once-weekly isoniazid and rifapentine (3 HP), 4 months of daily rifampicin (4 R), 3 months of daily isoniazid and rifampicin (3HR), 1 month of daily isoniazid and rifapentine (1 HP) in contrast to the 6–9 month isoniazid containing regimens (6 H, 9 H) used earlier in view of evidence from randomised controlled trials (RCTs) on these shorter regimens. The WHO also made a conditional recommendation on expanding the priority population to include to household contacts of patients with pulmonary tuberculosis of all ages, in addition to household contacts < 5 years and those with HIV infection. The RCTs of the 3 HP regimen in HIV negative individuals were conducted mainly in low TB burden countries like USA and Canada, while those in HIV positive individuals were conducted also in countries like South Africa. The 3 HP regimen is in the process of roll-out in programmatic management of tuberculosis preventive treatment in higher TB burden countries like India, that were not represented in these trials. There are some concerns about the 3 HP regimen in this process related to its safety profile, dosing, and need for co-administration of pyridoxine. The WHO has announced that it will be updating its guidance for tuberculosis preventive treatment soon and it is hoped that this viewpoint will be taken into consideration in this process.

---

### Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV [^111gci8n]. HIV.gov (2025). High credibility.

Mycobacterium tuberculosis (TB) disease — drug-susceptible TB treatment includes an Intensive Phase (8 Weeks) with INH (plus pyridoxine) plus (RIF or RFB) plus PZA plus EMB PO daily (AI), with the note that if drug-susceptibility report shows sensitivity to INH and RIF, then EMB may be discontinued before the end of 2 months (AI); the Continuation Phase uses INH (plus pyridoxine) plus (RIF or RFB) PO daily (AI), and for pulmonary, uncomplicated TB the total duration is 6 months (BII). An alternative regimen is specified only for patients receiving an efavirenz-based ARV regimen and is not recommended for extrapulmonary TB: Intensive Phase (8 Weeks) INH plus RPT 1,200 mg plus moxifloxacin 400 mg plus PZA plus pyridoxine 25–50 mg PO daily (AI); Continuation Phase (9 Weeks) INH plus RPT 1200 mg plus moxifloxacin 400 mg plus pyridoxine 25–50 mg PO daily (AI). Additional comments state that DOT is recommended for all patients (AII), that all rifamycins may have significant pharmacokinetic interactions with ARV drugs and to refer to dosing recommendations, and that therapeutic drug monitoring should be considered in patients receiving rifamycin and interacting ART.

---

### Guidelines for the prevention and treatment of opportunistic infections among HIV-exposed and HIV-infected children: recommendations from CDC, the National Institutes of Health, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics [^117HYjy8]. MMWR: Recommendations and Reports (2009). Medium credibility.

Tuberculosis adjuncts in HIV-infected children — prednisone and pyridoxine: Use is noted for complications in TB pericarditis (AII) and it "can be considered with severe airway obstruction related to endobronchial TB and highly symptomatic TB IRIS (BIII)". Prednisone 1–2 mg/kg body weight/day for 4 to 6 weeks is advisable, tapered over 2 weeks. Pyridoxine 1–2 mg/kg body weight/day (max 50 mg/day) is recommended for all HIV-infected children treated with isoniazid (AII).

---

### Reconsidering the role of isoniazid in drug-resistant tuberculosis [^116mQ5Vr]. American Journal of Respiratory and Critical Care Medicine (2024). Medium credibility.

Although the short-term safety of the higher dosing strategy appeared acceptable in INHindsight, doses of more than 5 mg/kg were historically usually used for intermittent therapy and have not been extensively evaluated in randomized studies under conditions of daily dosing. In the Katiyar trial, participants on higher doses had a higher incidence of peripheral neuropathy, despite pyridoxine prophylaxis. Slow acetylators, who may be most likely to benefit from higher doses, would also be subject to a higher risk of side effects, particularly drug-induced liver injury. Doses higher than 20 mg/kg have rarely been described in the literature, and a truly personalized dosing strategy would require access to practical and cost-effective methods of determining NAT2 status, which are not currently commercially available.

INHindsight suggests that higher-dose INH can only be expected to be effective in a minority of people who harbor inhA-mutated strains alone. It may, therefore, retain a role in individualized MDR-TB regimens based on genotypic susceptibility testing or in the minority whose strains are rifampicin monoresistant. In the context of standardized regimens, for which people with katG-mutated strains are currently considered eligible, these new data suggest that the balance of benefits and harms is likely to be adverse. Although many national TB programs have deployed shorter regimens containing higher-dose INH in recent years, to the benefit of patients with MDR-TB globally, alternative regimens containing fewer drugs at even shorter durations and containing no residual first-line drugs have already been recommended by the World Health Organization. The wider lesson of this work is that there is a need for a clearer framework in which developers of novel TB regimens can intelligently integrate information about pharmacology, susceptibility, and outcomes to prioritize the best regimens for pivotal clinical trials. Although the case of INH may be a special one, the innovative approach of INHindsight points the way to more rational construction of dose-optimized regimens in drug-resistant TB.

---

### Guidelines for the prevention and treatment of opportunistic infections in children with and exposed to HIV [^1129gcPo]. HIV.gov (2025). High credibility.

Pediatric HIV taking isoniazid or cycloserine — pyridoxine supplementation: Pyridoxine supplementation (1–2 mg/kg body weight/day, max 50 mg/day) is recommended for all children with HIV who are taking isoniazid or cycloserine, as treatment with isoniazid or cycloserine can result in relative pyridoxine deficiency and neurologic adverse events; consequently, adjunctive treatment with pyridoxine is recommended in these groups to reduce the likelihood of neurologic adverse events.

---

### Updates on the treatment of drug-susceptible and drug-resistant tuberculosis: an official ATS / CDC / ERS / IDSA clinical practice guideline [^112nfNNG]. American Journal of Respiratory and Critical Care Medicine (2025). High credibility.

Isoniazid-susceptible, rifampin-susceptible TB in adults — Recommended 4-mo Rifapentine-Moxifloxacin–Containing Regimen includes isoniazid 300 mg daily for 17 wk, rifapentine 1,200 mg daily for 17 wk, pyrazinamide weight-based dosing daily for 8 wk: 40 to < 55 kg: 1,000 mg; ≥ 55–75 kg: 1,500 mg; > 75 kg: 2,000 mg, and moxifloxacin 400 mg daily for 17 wk. Medications should be administered 7 d/wk with food, avoiding milk, antacids, or other cationic items, with DOT 5 of 7 days per week, and pyridoxine (vitamin B6), 25–50 mg/d, should be given with isoniazid to all patients.

---

### 36th international symposium on intensive care and emergency medicine: brussels, belgium. 15–18 March 2016 [^117J4jVN]. Critical Care (2016). Low credibility.

1 Tan Tock Seng Hospital, Singapore, Singapore; 2 National Neuroscience Institute, Singapore, Singapore

Introductions: HAGMA is a commonly encountered acid-base disorder in clinic practice. Multiple mnemonics were proposed to cover the common underlying causes – "GOLDMARK(1)", "KUSMALE", "KARMEL" and, of course, "MUDPILES". The "I" in "MUDPILES" represents some rare causes of HAGMA including "I"ron, "I"soniazid and "I"nborn errors of metabolism. We present a rare case of HAGMA secondary to isoniazid (INH) overdose.

Methods: A 41 year old male was intubated for status epilepticus. He had a medical history of pulmonary tuberculosis (pTB) and had been treated with a course of rifampicin, INH and ethambutol since 6 months ago.

Results: Arterial blood gas in the Emergency Department showed severe metabolic and respiratory acidosis; pH 6.76, pCO2 80, pO2 62, HCO3 11, BE -24. The initial anion gap was 26. Physical examination was unremarkable except for fever and hypotension. Neurological examination did not reveal any lateralising signs. CT scan of the brain was normal. Mild renal impairment, and lactate acidosis resolved rapidly with initial fluid resuscitation. Serum and urine toxicology for commonly encountered drugs were also negative. Patient regained orientation on day 3 of intubation and was promptly extubated. Further history revealed that he had consumed a bottle of isoniazid tablets after an altercation with his wife the same night.

Conclusions: Tuberculosis is endemic is South East Asia. INH is one of the four drugs used in the treatment of this disease. Side effects of isoniazid range from mild hepatotoxicity to the potentially fatal INH hepatitis. HAGMA refractory to conventional therapy is one of the hallmarks of INH toxicity. Though it is one of the rare causes of HAGMA, prompt diagnosis and treatment with high dose pyridoxine (2) reduces mortality and morbidity.

References

1. Mehta AN, Emmett JB, Emmett M. GOLD MARK: an anion gap mnemonic for the 21st century. Lancet. 2008;372(9642):892.

2. Orlowski JP, Paganini EP, Pippenger CE. Treatment of a potentially lethal dose isoniazid ingestion. Ann Emerg Med. 1988;17(1):73–6.

---

### Pharmacokinetics and safety of 3 months of weekly rifapentine and isoniazid for tuberculosis prevention in pregnant women [^112gU1Zr]. Clinical Infectious Diseases (2022). Medium credibility.

METHODS

The International Maternal Pediatric Adolescent AIDS Clinical Trial Network (IMPAACT) 2001 study (NCT02651259) was a phase I/II, open-label, PK and safety study of 3HP among pregnant women living with and without HIV, with an indication for TB preventive therapy. Participants were enrolled in Haiti, Kenya, Malawi, Thailand, and Zimbabwe. Cohort 1 enrolled second-trimester women (≥ 14 to < 28 weeks' gestation, n = 25), and cohort 2 enrolled third-trimester women (≥ 28 to ≤ 34 weeks' gestation, n = 25) (Figure 1). Participants received 12 directly observed, once-weekly doses of RPT (900 mg) and INH (900 mg), with pyridoxine. RPT was donated by Sanofi; INH was purchased from Macleod. Treatment completion was defined as receipt of at least 11 doses over 16 weeks.

Figure 1.
CONSORT diagram and study schema: CONSORT flow diagram showing participant flow through the IMPAACT 2001 trial. Abbreviations: CONSORT, Consolidated Standards of Reporting Trials; DOT, directly observed therapy; GA/gest age, gestational age; IMPAACT, International Maternal Pediatric Adolescent AIDS Clinical Trial Network; PK, pharmacokinetics; TB, tuberculosis.

Participants

Eligibility requirements included age of 18 years or older, singleton pregnancy by ultrasound with gestational age of 14–34 weeks, high risk for TB (household contact with pulmonary TB, or WLHIV with latent TB), and the following laboratory values: hemoglobin of 7.5 g/dL or greater, white blood cell count of 1500 cells/mm³ or greater, absolute neutrophil count of 750 cells/mm³ or greater, platelet count of 100 000/mm³ or greater, alanine aminotransferase less than 2.5 times the upper limit of normal (ULN), and total bilirubin less than 1.6 times the ULN. Women living with HIV had to be taking an efavirenz (EFV)-based antiretroviral regimen (ART). Exclusion criteria included active TB within 2 years, treatment for latent TB, personal history or exposure to drug-resistant TB, fetal abnormality by ultrasound, liver cirrhosis, or peripheral neuropathy. Mother–infant pairs were followed until 24 weeks postpartum.

---

### What do we know about micronutrients in critically ill patients? A narrative review [^1122dbbn]. JPEN: Journal of Parenteral and Enteral Nutrition (2025). Medium credibility.

Plasma concentrations in critically ill patients

During critical illness, vitamin B 6 deficiency can result from malnutrition, increased demands, and medications interfering with its metabolism. Risk factors include HIV infection and treatment, alcoholic hepatitis, chemotherapy or radiotherapy, tuberculosis treatment with isoniazide, and chronic kidney and liver diseases. Vitamin B 6 status (plasma and erythrocyte PLP) may boost the antioxidant activity in surgical ICU patients. Two observational studies tested the association between vitamin B 6 status and clinical outcomes (see Table S7). No association was found between vitamin B 6 intake or status and ICU or hospital length of stay or ventilation duration. However, Acute Physiology and Chronic Health Evaluation II (APACHE II) scores were significantly lower on ICU day 7 in patients with plasma PLP ≥ 20 nmol/L compared with < 20 nmol/L measured on day 1.

Clinical studies testing high doses

In ICU patients, vitamin B 6 can support protein metabolism and immune response and prevent or treat peripheral neuropathy and seizures. In vitamin B 6 –deficient patients, impaired cellular immunity has been reported, mainly because of a low T 4 lymphocyte count. Fourteen days of pyridoxine supplementation (50–100 mg/day) led to a significant increase in the total lymphocytic count as well as the T‐helper and T‐suppressor cells compared with the control group in an interventional ICU study (n = 51),(see Table S8). It was also suggested to prevent and treat anemia, particularly sideroblastic anemia. Recently, Wang et al showed no 28‐day mortality benefit when supplementing IV vitamin B 6 (300 mg/day for 1 week) vs 0.9% saline to 128 patients with sepsis and AKI. However, it reduced ICU stay, improved renal functions at day 7, diminished inflammatory markers (interleukin [IL] 6, IL‐8, tumor necrosis factor alpha, and endothelin‐1), and mitigated the oxidative stress (superoxide dismutase [SOD], glutathione, and malondialdehyde). Nevertheless, the small sample size and lower mortality than expected by the APACHE II score warrant further studies. It is important to monitor vitamin B 6 levels, because prolonged high doses can lead to toxicity manifested predominantly as peripheral neuropathy.

---

### How to manage neonatal tuberculosis [^115z53Va]. Journal of Perinatology (2016). Low credibility.

This article reports the recommendations for managing neonatal tuberculosis (TB) drawn up by a group of Italian scientific societies. The Consensus Conference method was used, and relevant publications in English were identified through a systematic review of MEDLINE and the Cochrane Database of Systematic Reviews from their inception until 31 December 2014. Group experts concluded that if suspicion is aroused, it is necessary to undertake promptly all of the investigations useful for identifying the disease not only in the newborn, but also in the mother and family contacts because a diagnosis of TB in the family nucleus can guide its diagnosis and treatment in the newborn. If the suspicion is confirmed, empirical treatment should be started. Breast-fed newborns being treated with isoniazid should be given pyridoxine supplementation at a dose of 1 mg/kg/day. Mothers with active-phase TB can breast-feed once they have become smear negative after having received appropriate treatment.

---

### Intravenous pyridoxine-induced metabolic acidosis [^117DFUWb]. Annals of Emergency Medicine (2001). Low credibility.

Study Objective

Pyridoxine hydrochloride, the antidote for isonicotinic acid hydrazide (INH) — induced seizures, is available in solution at a concentration of 100 mg/mL at a pH of less than 3. Pyridoxine is often infused rapidly in large doses for INH-induced seizures. Effects of pyridoxine infusion on base deficit in amounts given for INH poisoning have not been studied in human subjects. We hypothesized that this infusion would result in transient worsening of acidosis.

Methods

We conducted a randomized, controlled crossover trial in human volunteers. Five healthy volunteers (mean age, 35 years; range, 29 to 43 years) were randomized to receive intravenous placebo (50 mL of normal saline solution) or 5 g of pyridoxine (50 mL) over 5 minutes. A peripheral intravenous catheter was established in each arm, and a heparinized venous blood sample was obtained for base deficit at baseline and 3, 6, 10, 20, and 30 minutes after infusion. After at least a 1-week washout period, the volunteers were assigned to the alternate arms of the experiments, thus acting as their own control subjects. Data were analyzed by using the 2-tailed paired t test, controlling for multiple comparisons.

Results

No difference was noted between groups at baseline. A statistically significant increased base deficit was noted after the pyridoxine infusion versus control at 3 to 20 minutes but not at 30 minutes (P = 0.1). Maximal mean increase in base deficit (2.74 mEq/L) was noted at 3 minutes.

Conclusion

A transient increase in base deficit occurs after the infusion of 5 g of pyridoxine in normal volunteers.

---

### Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV [^111sMRog]. HIV.gov (2025). High credibility.

Dosing recommendations for use of antiretroviral (ARV) and anti-TB drugs for active drug sensitive TB — isoniazid and rifampin: Isoniazid daily dose is 5 mg/kg (usual dose 300 mg), and use INH with pyridoxine 25–50 mg PO daily. For rifampin, compatible ARV options listed are NRTIs (use TAF with caution) and DTG, RAL (twice daily), MVC without a strong CYP3A4 inhibitor (note: doses of these ARVs need to be adjusted when used with rifampin); the daily rifampin dose is 10 mg/kg (usual dose 600 mg).

---

### Isoniazid-associated pellagra during mass scale-up of tuberculosis preventive therapy: a case-control study [^112UCLc8]. The Lancet: Global Health (2022). High credibility.

Introduction

Pellagra is caused by niacin (vitamin B3) deficiency, presents with a characteristic rash, and is diagnosed clinically. Advanced pellagra that is untreated can cause death. Unfortified maize is low in bioavailable niacin and Malawians are high maize consumers. In Malawi, 85% of maize is locally processed (ie, where it is produced) and rarely fortified; less than half of the centrally processed maize is fortified. An under-diversified diet based on subsistence maize is a risk factor for pellagra.

Isoniazid prevents tuberculosis and deaths in people living with HIV. However, isoniazid has been implicated as a secondary cause of pellagra by inhibiting niacin production from the amino acid tryptophan.HIV infection also disrupts tryptophan catabolism and can lower intracellular niacin. Despite decades of efforts by international agencies and national programmes to distribute tuberculosis preventive treatment among people living with HIV, large-scale implementation had been scarce until recently. In 2018, the UN General Assembly declared a goal to give tuberculosis preventive treatment to 30 million people (including 6 million people living with HIV) by 2022. The US President's Emergency Plan for AIDS Relief (PEPFAR) also set an ambitious target of providing tuberculosis preventive treatment to 13 million people living with HIV by 2022. The Malawi Ministry of Health revised national guidelines to provide daily, continuous isoniazid with vitamin B6 (pyridoxine) for people living with HIV in the highest burden districts facing generalised epidemics of HIV and tuberculosis. From Aug 1 to Oct 31, 2017, more than 250 000 people living with HIV across five districts in Malawi initiated isoniazid preventive treatment (IPT; adult dose: 300 mg isoniazid plus 25 mg vitamin B6 [pyridoxine]). Within 3 months, which coincided with the annual food-scarce season, clinicians noticed an increased incidence of pellagra among people living with HIV and taking IPT. We hypothesised that large-scale isoniazid exposure in Malawi contributed to the cumulative risk for pellagra in a nutritionally vulnerable population.

---

### The 3 HP regimen for tuberculosis preventive treatment: safety, dosage and related concerns during its large-scale implementation in countries like India [^116dYhwy]. The Lancet Regional Health: Southeast Asia (2024). High credibility.

Summary

The 3-month once-weekly isoniazid-rifapentine (3 HP) regimen for tuberculosis preventive treatment recommended by WHO is being rolled in countries including India. It has higher completion rates and lower risk of hepatotoxicity than isoniazid preventive treatment, but trials also showed higher frequency of systemic drug reactions (SDRs) including flu-like syndromes and dizziness, and also uncommon Grade 3 or 4 adverse events like hypotension, syncope, bronchospasm. Low BMI is a risk factor for SDRs. Available data on safety of 3 HP in the Asian region is limited, heterogeneous, but points to a higher frequency of SDRs suggesting a need for caution in its large-scale implementation. 19% (118/614) of household contacts initiated on 3 HP in Delhi reported dizziness. Multiple lines of evidence including pharmacokinetic data suggest that the SDRs may be related to isoniazid and its plasma concentration. WHO and national guidelines for the 3 HP regimen currently recommend a fixed dose of once-weekly 900 mg isoniazid in adults regardless of body weight that poses a risk of SDRs for lower weight adults, amplified by the acetylator status and the lack of co-administration of pyridoxine. Weight based dosing, co-administration of pyridoxine and pharmacovigilance studies should accompany the roll out of 3 HP to ensure its safe and successful implementation.

---

### Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV [^113G7HMo]. HIV.gov (2025). High credibility.

Treating latent tuberculosis infection (LTBI) — alternative therapy options are: isoniazid 300 mg PO daily plus pyridoxine 25–50 mg PO daily for 6–9 months (AII); rifampin 600 mg PO daily for 4 months (BI) (4R), with instruction to consult the Tuberculosis/HIV Coinfection section of the Adult and Adolescent Antiretroviral Guidelines for ARV compatibility; and isoniazid 300 mg PO daily plus rifapentine (see weight-based dosing below) PO daily plus pyridoxine 25–50 mg PO daily for 4 weeks (BI) (1HP). The page notes, "1HP is recommended only for patients receiving an efavirenz-based ARV regimen (AI)", and provides rifapentine daily dosing tiers: Weighing < 35 kg: 300 mg; Weighing 35–45 kg: 450 mg; Weighing > 45 kg: 600 mg (maximum 600 mg). For people exposed to drug-resistant TB, drugs for prevention of TB should be selected after consultation with experts and with public health authorities (AIII).

---

### Pyridoxine hci [^1115tJZX]. FDA (2024). Medium credibility.

CONTRAINDICATIONS

A history of sensitivity to pyridoxine or to any of the ingredients in Pyridoxine Hydrochloride Injection, USP is a contraindication.

---

### An official ATS workshop report: emerging issues and current controversies in HIV-associated pulmonary diseases [^115eR7M6]. Proceedings of the American Thoracic Society (2011). Medium credibility.

Tuberculosis in HIV — diagnosis and treatment guidance indicates that IFN-γ release assays (IGRAs) are more sensitive and specific than tuberculin skin tests for detecting latent tuberculosis infection (LTBI) and are less affected by low CD4+ counts; treatment of LTBI in HIV-infected individuals is strongly recommended with a preferred regimen of 9 months of isoniazid and pyridoxine; for active TB, a once-weekly rifapentine regimen is not recommended, and twice-weekly rifampin or rifabutin are not recommended in persons with a CD4+ T cell count less than 100 cells/μl; ensuring completion via directly observed therapy is highly recommended, and clinicians must be alert for drug–drug interactions and immune reconstitution inflammatory syndrome.

---

### Guidelines for the prevention and treatment of opportunistic infections in children with and exposed to HIV [^112BKCQG]. HIV.gov (2025). High credibility.

Dosing recommendations for preventing and treating TB in children with HIV — adjunctive pyridoxine with isoniazid: Pyridoxine 1–2 mg/kg body weight once daily (maximum 25–50 mg/day) with isoniazid is recommended for exclusively breastfed infants, children and adolescents on meat- and milk-deficient diets, children with nutritional deficiencies including all children with HIV, and pregnant girls and women.

---

### The 3 HP regimen for tuberculosis preventive treatment: safety, dosage and related concerns during its large-scale implementation in countries like India [^111sT9Pn]. The Lancet Regional Health: Southeast Asia (2024). High credibility.

The way forward

There is paucity of data around safety profile of 3 HP in high TB burden countries but the available evidence suggests that adverse events are frequent, mostly well-tolerated, but may be severe and could lead to discontinuation of therapy. It is critical to minimise the possibility of adverse effects as their occurrence can not only cause individual harm but also undermine public confidence in this preventive intervention. The uniform dose of 900 mg isoniazid across adult weights of 30–70 kg is inappropriate for a lower weight Indian population and the program should consider weight-based dosing with narrower bands that are already used in treatment of patients with tuberculosis. A representative profile of the population with regard to acetylator status is needed. Pyridoxine should be available for co-administration with higher dose isoniazid in light of prevalent pyridoxine deficiency and undernutrition, diabetes, alcohol use. The NTEP could implement the 3 HP with weight-appropriate doses and co-administration of pyridoxine, with appropriate monitoring of persons and collection of data on adverse events. The NTEP may also consider alternative regimens of TPT recommended by WHO (1 HP and 4 R) that have not been associated with systemic drug reactions and flu like syndromes. There is a need also to generate pharmacological and clinical evidence to tailor TPT interventions like 3 HP to different populations.

---

### Rifapentine (Priftin) [^114pa8Sj]. FDA (2025). Medium credibility.

14.1 Active Pulmonary Tuberculosis

PRIFTIN was studied in two randomized, open-label controlled clinical trials in the treatment of active pulmonary tuberculosis.

The first trial was an open-label, prospective, parallel group, active-controlled trial in HIV-negative patients with active pulmonary tuberculosis. The population mostly comprised Black (approximately 60%) or multiracial (approximately 31%) patients. Treatment groups were comparable for age and sex and consisted primarily of male subjects with a mean age of 37 ± 11 years. In the initial 2-month phase of treatment, 361 patients received PRIFTIN 600 mg twice a week in combination with daily isoniazid, pyrazinamide, and ethambutol and 361 subjects received rifampin 600 mg in combination with isoniazid, pyrazinamide and ethambutol all administered daily. The doses of the companion drugs were the same in both treatment groups during the initial phase: isoniazid 300 mg, pyrazinamide 2000 mg, and ethambutol 1200 mg. For patients weighing less than 50 kg, the doses of rifampin (450 mg), pyrazinamide (1500 mg) and ethambutol (800 mg) were reduced. Ethambutol was discontinued when isoniazid and rifampin susceptibility testing results were confirmed. During the 4-month continuation phase, 317 patients in the PRIFTIN group continued to receive PRIFTIN 600 mg dosed once weekly with isoniazid 300 mg and 304 patients in the rifampin group received twice weekly rifampin and isoniazid 900 mg. For patients weighing less than 50 kg, the doses of rifampin (450 mg) and isoniazid (600 mg) were reduced. Both treatment groups received pyridoxine (Vitamin B6) over the 6-month treatment period. Treatment was directly observed. 65/361 (18%) of patients in the PRIFTIN group and 34/361 (9%) in the rifampin group received overdoses of one or more of the administered study medications during the initial or continuation phase of treatment. Seven of these patients had adverse reactions reported with the overdose (5 in the PRIFTIN group and 2 in the rifampin group).

---

### A semimechanistic model of the bactericidal activity of high-dose isoniazid against multidrug-resistant tuberculosis: results from a randomized clinical trial [^111mYSSV]. American Journal of Respiratory and Critical Care Medicine (2021). Medium credibility.

Rationale: There is accumulating evidence that higher-than-standard doses of isoniazid are effective against low-to-intermediate-level isoniazid-resistant strains of Mycobacterium tuberculosis, but the optimal dose remains unknown. Objectives: To characterize the association between isoniazid pharmacokinetics (standard or high dose) and early bactericidal activity against M. tuberculosis (drug sensitive and inhA mutated) and N-acetyltransferase 2 status. Methods: ACTG (AIDS Clinical Trial Group) A5312/INHindsight is a 7-day early bactericidal activity study with isoniazid at a normal dose (5 mg/kg) for patients with drug-sensitive bacteria and 5, 10, and 15 mg/kg doses for patients with inhA mutants. Participants with pulmonary tuberculosis received daily isoniazid monotherapy and collected sputum daily. Colony-forming units (cfu) on solid culture and time to positivity in liquid culture were jointly analyzed using nonlinear mixed-effects modeling. Measurements and Main Results: Fifty-nine adults were included in this analysis. A decline in sputum cfu was described by a one-compartment model, whereas an exponential bacterial growth model was used to interpret time-to-positivity data. The model found that bacterial kill is modulated by isoniazid concentration using an effect compartment and a sigmoidal Emax relationship (a model linking the drug concentration to the observed effect). The model predicted lower potency but similar maximum kill of isoniazid against inhA-mutated compared with drug-sensitive isolates. Based on simulations from the pharmacokinetics-pharmacodynamics model, to achieve a drop in bacterial load comparable to 5 mg/kg against drug-sensitive tuberculosis, 10- and 15-mg/kg doses are necessary against inhA-mutated isolates in slow and intermediate N-acetyltransferase 2 acetylators, respectively. Fast acetylators underperformed even at 15 mg/kg. Conclusions: Dosing of isoniazid based on N-acetyltransferase 2 acetylator status may help patients attain effective exposures against inhA-mutated isolates. Clinical trial registered with www.clinicaltrials.gov (NCT01936831).

---

### The 3 HP regimen for tuberculosis preventive treatment: safety, dosage and related concerns during its large-scale implementation in countries like India [^112ZrDFg]. The Lancet Regional Health: Southeast Asia (2024). High credibility.

Table 2
Isoniazid doses for different indications in adults.

Adult weights in India are lower than in other populations, and extrapolation of fixed doses should be avoided. In the PREVENT trial the median (interquartile range) BMI was 27 (23–31) kg/m², the median weight was 67 kg, and the dose of 900 mg was appropriate to the weight in this population. In contrast the mean BMI in Indian adult men and women according to recent data was 22.8 (4.1) kg/m² and 22.61 (4.5) kg/m². In the RATIONS trial the weights of the adult household contacts who were men and women were 51.1 kg and 42.6 kg respectively. A cautionary note on the higher frequency of adverse events in Indian patients due to use of these fixed doses that were inappropriate in an Indian context was sounded in a 1986 paper". There is a tendency for Indian patients to receive high drug dosages in terms of body weight, as fixed doses which have been established for heavier Western patients are transferred without adjustment to light-weight Indian patients". However, the technical guideline for the national tuberculosis programme in India in 1997 mentioned with regard to drug doses for adults "For adults, drugs will be given in the recommended number of pills/capsules irrespective of body weight". The dose of isoniazid recommended was 600 mg three times a week, at a time when the WHO recommendations for isoniazid dosing was 10 mg/kg (8–12 mg/kg) three times a week. In an article in 2008, we drew attention to the low weights seen in Indian patients that we had documented and pointed that a single uniform dose regardless of weight in adults was resulting in potentially toxic doses for adults in the lower weight ranges. A detailed evaluation across 4 states of India showed that adverse effects of medicines including weakness and dizziness were identified as the most frequent cause of interruption of treatment. Over the last few decades the programme did establish weight-based dosing for patients with tuberculosis where underweight patients got weight-appropriate doses. This past experience with tailoring anti-tuberculosis drug doses to weights in India should inform current recommendations and practice.
2 The acetylator status of Indians and the risk for adverse events.

---

### Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America [^114FsjNb]. MMWR: Recommendations and Reports (2009). Medium credibility.

Preferred and alternative drugs for LTBI in HIV — isoniazid regimen and completion: Isoniazid prophylaxis for 9 months remains a preferred therapy (AI) and should be supplemented with pyridoxine at a dose of 25 to 50 mg/day to prevent peripheral neuropathy (AIII); the risk of hepatitis is not significantly increased when isoniazid is combined with efavirenz- or nevirapine-based regimens, but a significant disadvantage is that the majority of patients do not complete all 9 months, and patients are more likely to complete shorter regimens.

---

### Guidelines for the prevention and treatment of opportunistic infections in children with and exposed to HIV [^113wi88x]. HIV.gov (2025). High credibility.

Tuberculosis (TB) adjuvant treatment and special issues — children with and exposed to HIV: Adjuvant treatment includes co-trimoxazole prophylaxis; pyridoxine 1–2 mg/kg body weight/day (maximum 25–50 mg/day) with isoniazid or cycloserine/terizidone, if malnourished, and pyridoxine supplementation is recommended for exclusively breastfed infants and for children and adolescents on meat- and milk-deficient diets; children with nutritional deficiencies, including all children with HIV; and pregnant girls and women; corticosteroids (2 mg/kg body weight per day of prednisone [maximum 60 mg/day] or its equivalent for 4–6 weeks followed by tapering) with TB meningitis; may be considered with pleural effusions, pericarditis, severe airway compression, or severe IRIS; for second-line drug doses, consult with an expert as dosing guidelines continue to evolve with emerging data; some experts recommend using a daily rifampin dose of 20–30 mg/kg/day for infants and toddlers.

---

### Guidelines for the prevention and treatment of opportunistic infections in children with and exposed to HIV [^112Q8xQ1]. HIV.gov (2025). High credibility.

Primary prophylaxis of tuberculosis (TB) exposure in children with and exposed to HIV includes a weekly 12-dose combination of isoniazid 15 mg/kg (rounded up to the nearest 50 or 100 mg; 900 mg maximum) with rifapentine dosed by weight as 10–14.0 kg: 300 mg; 14.1–25.0 kg: 450 mg; 25.1–32.0 kg: 600 mg; 32.1–49.9 kg: 750 mg; and ≥ 50.0 kg: 900 mg maximum; an alternative is isoniazid 10–15 mg/kg (max 300 mg) daily for 6–9 months; for isoniazid-resistant source cases, daily rifampin 15–20 mg/kg (maximum 600 mg/day) for 4 months is recommended, and for isoniazid- and rifampin-resistant (MDR-TB) cases consultation with a TB expert and local public health authorities is advised; drug–drug interactions with antiretroviral therapy (ART) should be considered for rifamycin-containing alternatives; prophylaxis should be discontinued only with documented severe adverse events; and adjunctive pyridoxine 1–2 mg/kg once daily (maximum 25–50 mg/day) with isoniazid is recommended for the specified groups.

---

### Isoniazid [^115q2eiN]. FDA. Low credibility.

The dosage of isoniazid PO for treatment of Mycobacterium kansasii in adults is:

- **Maintenance**: 5 mg/kg PO daily
- **Maximum**: 300 mg per day

---

### Guidelines for the prevention and treatment of opportunistic infections in children with and exposed to HIV [^1166aTwG]. HIV.gov (2025). High credibility.

Pyridoxine prophylaxis during isoniazid or cycloserine therapy — Treatment with isoniazid or cycloserine "can result in neurologic adverse events, which are related to relative pyridoxine deficiency", and "children with nutritional deficiencies and those with HIV are at particular risk of isoniazid-associated neuropathy". Accordingly, Pyridoxine (1–2 mg/kg body weight/day, maximum 50 mg/day) is recommended for all children with HIV treated with isoniazid or cycloserine (expert opinion).

---

### Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV [^1135yUov]. HIV.gov (2025). High credibility.

3HR regimen for LTBI in people with HIV: Daily isoniazid 300 mg PO daily plus rifampin 600 mg PO daily plus pyridoxine 25 mg to 50 mg PO daily for 3 months is also a preferred option for the treatment of LTBI in people with HIV (AI). Among people with HIV, several studies found no difference in the incidence of TB disease between those who received 3HR and those who received ≥ 6 months of daily isoniazid, and hepatotoxicity was less frequent among those receiving 3HR, but treatment-limiting adverse effects were more common.

---

### Pyridoxine hydrochloride [^116je9Bv]. FDA (2024). Medium credibility.

DOSAGE AND ADMINISTRATION:

Pyridoxine Hydrochloride Injection may be administered intramuscularly or intravenously. In cases of dietary deficiency, the dosage is 10 to 20 mg daily for 3 weeks. Follow-up treatment is recommended daily for several weeks with an oral therapeutic multivitamin preparation containing 2 to 5 mg pyridoxine. Poor dietary habits should be corrected, and an adequate, well balanced diet should be prescribed.

The vitamin B6dependency syndrome may require a therapeutic dosage of as much as 600 mg a day and a daily intake of 30 mg for life.

In deficiencies due to INH, the dosage is 100 mg daily for 3 weeks followed by a 30 mg maintenance dose daily.

In poisoning caused by ingestion of more than 10 g of INH, an equal amount of pyridoxine should be given — 4 g intravenously followed by 1 g intramuscularly every 30 minutes.

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.

---

### Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV [^116sbft2]. HIV.gov (2025). High credibility.

Latent tuberculosis infection (LTBI) regimen 1HP in people with HIV — dosing, efficacy, and antiretroviral therapy (ART) considerations: Isoniazid 300 mg PO daily plus rifapentine (weight-based dosing to a maximum of 600 mg) PO daily plus pyridoxine 25 mg to 50 mg PO daily for 4 weeks (1HP) is an alternative therapy for LTBI with efavirenz (BI). In the BRIEF-TB study (ACTG 5279) of people with HIV in high-burden settings (TB incidence > 60 per 100,000), the median CD4 count was 470 cells/mm³, 50% were on efavirenz or nevirapine, and 21% were TST positive; 1HP was non-inferior to 9H, with treatment completion 97% versus 90%. Documented LTBI based on TST or IGRA was 23%, and the overall event rate was 0.56/100 person-years after more than 3 years of follow-up. Based on these data, 1HP is recommended as an alternative regimen for LTBI in people with HIV (BI). If ART is administered with 1HP, an efavirenz-based regimen should be used (AI); a study of co-administration with dolutegravir is in progress and the use of dolutegravir-based ART should await results from this trial.

---

### Prevalence of neurotoxicity symptoms among postpartum women on isoniazid preventive therapy and efavirenz-based treatment for HIV: an exploratory objective of the IMPAACT P1078 randomized trial [^111kV2rL]. BMC Pregnancy and Childbirth (2023). Medium credibility.

Peripheral neuropathy is the most common side effect of INH. The low prevalence of peripheral neuropathy observed in this study could be attributable to the recommended supplementation with pyridoxine and that women with at least Grade 1 peripheral neuropathy were excluded from the study. Hepatitis C serology, age and BMI are factors already known to be associated with peripheral neuropathy. However, the protective effect of Cotrimoxazole was an unexpected finding in our study and requires further investigation.

In our study, there was no evidence of an association between timing of initiation of IPT during antepartum and postpartum, concomitant with EFV use, and increased frequencies of probable depression, cognitive dysfunction, sleep disturbances or peripheral neuropathy. Pharmacokinetic data from South African pregnant and postpartum women living with HIV found that INH reduced EFV clearance, especially among those with slow NAT2 acetylator status. Their study did not provide further data on whether the INH-induced increased EFV plasma concentration was associated with increased frequency of neurotoxicity symptoms in a non-pregnant population. This P1078 exploratory analysis showed no evidence of effect modification with IPT and concomitant EFV use. However, despite the suggestion from the data in our study that IPT and EFV can be taken by postpartum women without fear of increased risk of symptoms of neurotoxicity, further study is advised to formally assess the drug-drug interactions using a larger sample size.

Cotrimoxazole was the only risk factor associated with probable depression. This association with depression is already documented. Further study is advised to formally assess association of Cotrimoxazole with probable depression in peripartum women.

---

### Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America [^114ugSrg]. MMWR: Recommendations and Reports (2009). Medium credibility.

Mycobacterium tuberculosis (TB) disease — empiric therapy, first-line regimen, durations, drug-resistant approaches, and supportive measures: After collecting specimen for culture and molecular diagnostic tests, empiric TB treatment should be started in individuals with clinical and radiographic presentation suggestive of TB (AII). Initial phase is 2 months, given daily by DOT (AI), with INH (plus pyridoxine) plus (RIF or RFB) plus PZA plus EMB (AI), followed by continuation with INH (plus pyridoxine) plus (RIF or RFB) daily (AI). Total duration for pulmonary, drug-susceptible TB is 6 months (BII); for pulmonary TB with positive culture after 2 months of TB treatment or severe cavity or disseminated extrapulmonary TB it is 9 months (BII); for extra-pulmonary TB with CNS infection it is 9–12 months (BII). If rapid drug susceptibility testing (DST) indicates resistance to rifampin with or without other drugs, options include INH (plus pyridoxine) plus EMB plus PZA plus (moxifloxacin or levofloxacin) plus an aminoglycoside, or capreomycin (BII). For drug-resistant TB resistant to INH, use (moxifloxacin or levofloxacin) plus (RIF or RFB) plus EMB plus PZA for 6 months (BII); if resistant to rifampins plus or minus other drugs, therapy should include at least 5 active drugs and be individualized with consultation with experienced specialists (AIII). DOT is recommended for all patients (AI); all rifamycins may have significant pharmacokinetic interactions with ARV drugs, therapeutic drug monitoring should be considered in patients receiving rifamycin and interacting ART, adjunctive corticosteroids improve survival for TB with CNS involvement (AI), and paradoxical IRIS that is not severe can be treated with NSAIDs without a change in TB or HIV therapy (BIII).

---

### Ascorbic acid, calcium citrate, iron pentacarbonyl, cholecalciferol, pyridoxine hydrochloride, folic acid (citraNatal) [^114ttcsu]. FDA (2010). Low credibility.

CONTRAINDICATIONS

This product is contraindicated in patients with a known hypersensitivity to any of the ingredients.

---

### Pyridoxine hydrochloride [^114MunDs]. FDA (2024). Medium credibility.

CONTRAINDICATIONS:

A history of sensitivity to pyridoxine or to any of the ingredients in Pyridoxine Hydrochloride Injection, USP is a contraindication.

---

### Causes and timing of mortality and morbidity among late presenters starting antiretroviral therapy in the REALITY trial [^1139akU1]. Clinical Infectious Diseases (2018). Low credibility.

METHODS

The REALITY trial (ISRCTN43622374) recruited 1805 HIV-infected ART-naive adults and children ≥ 5 years (98% aged ≥ 13 years) from Zimbabwe, Uganda, Malawi, and Kenya with a CD4 count < 100 cells/µL. In brief, participants were randomized 1:1 to enhanced prophylaxis vs standard prophylaxis (cotrimoxazole), together with World Health Organization (WHO)–recommended combination ART comprising 2 nucleoside reverse transcriptase inhibitors (NRTIs) (tenofovir disoproxil fumarate + emtricitabine or zidovudine + lamivudine in adults) and 1 nonnucleoside reverse transcriptase inhibitor (NNRTI) (predominantly efavirenz). Enhanced prophylaxis comprised single-dose albendazole, 5 days of azithromycin, 12 weeks of fluconazole (100 mg), and 12 weeks of fixed-dose combination of cotrimoxazole (800/160 mg)/isoniazid (300 mg)/pyridoxine (25 mg) once daily. For children aged 5–12 years, doses were halved (except albendazole). Isoniazid/pyridoxine use post–week 12 depended on national isoniazid preventive therapy guidelines. Participants already receiving or needing antimicrobial treatment or prophylaxis received it outside the randomized design, and received other prophylaxis according to randomization. Participants were factorially randomized 1:1 to 12 weeks of raltegravir vs no raltegravir, and 12 weeks of ready-to-use supplementary food vs standard nutritional support; neither affected mortality (previously reported in). Adults and children's guardians gave written informed consent; older children gave additional assent following national guidelines. REALITY was approved by ethics committees in Zimbabwe, Uganda, Malawi, Kenya, and the United Kingdom.

Clinical events occurring through 48 weeks were ascertained at trial visits (see Supplementary Methods). Adverse events (AEs) were graded following standard tables. Serious adverse events (SAEs) were those leading to death, being life-threatening, causing/prolonging hospitalization, or causing permanent disability, or were other medical conditions with a risk of 1 of these categories.

---

### Adequacy of recommendations for adverse event management in national and international treatment guidelines for rifampicin-susceptible tuberculosis: a systematic review [^117UEsk3]. EClinicalMedicine (2025). Medium credibility.

The use of tables, figures, and algorithms can help users find key recommendations quickly and work through complex clinical decision-making, as in the management of suspected drug-induced liver injury. Half of the guidelines contained at least one table or figure devoted to adverse event management (Table 3, Supplementary Materials, pages 14–15).

Table 3
Ease of use and specificity of recommendations among guidelines providing recommendations for adverse event management (n, %).

The inclusion and numbers of such tables and figures paralleled the presence of recommendations for adverse event management, being more common in non-governmental and high-burden country guidelines. There were gaps in providing clear direction to sections on adverse event management. For example, the United States treatment guideline included adverse event management in a section entitled "Practical aspects of treatment". Only 5 guidelines included functional weblinks to additional information. 27 guidelines (59%) contained recommendations for specific medications for treatment of adverse events, 19 of which included recommendations for specific doses. Notably, most of these specific recommendations were for pyridoxine for the treatment of neuropathy (Table 3, Supplementary Materials pages 14–15). Three guidelines included notes about drug–drug interactions that may affect treatment of adverse events, though no guidelines noted the drug–drug interactions between rifampicin and commonly used anti-emetic medications (ondansetron, metoclopramide), and a commonly used proton-pump inhibitor (omeprazole).

---

### Isoniazid [^116uu81B]. FDA (2025). Medium credibility.

CLINICAL PHARMACOLOGY

Within 1 to 2 hours after oral administration, isoniazid produces peak blood levels which decline to 50 percent or less within 6 hours. It diffuses readily into all body fluids (cerebrospinal, pleural and ascitic fluids), tissues, organs and excreta (saliva, sputum and feces). The drug also passes through the placental barrier and into milk in concentrations comparable to those in the plasma. From 50 to 70 percent of a dose of isoniazid is excreted in the urine in 24 hours.

Isoniazid is metabolized primarily by acetylation and dehydrazination. The rate of acetylation is genetically determined. Approximately 50 percent of Blacks and Caucasians are "slow inactivators" and the rest are "rapid inactivators"; the majority of Eskimos and Orientals are rapid inactivators".

The rate of acetylation does not significantly alter the effectiveness of isoniazid. However, slow acetylation may lead to higher blood levels of the drug and, thus, to an increase in toxic reactions.

Pyridoxine (vitamin B6) deficiency is sometimes observed in adults with high doses of isoniazid and is considered probably due to its competition with pyridoxal phosphate for the enzyme apotryptophanase.

Mechanism of Action

Isoniazid inhibits the synthesis of mycoloic acids, an essential component of the bacterial cell wall. At therapeutic levels isoniazid is bactericidal against actively growing intracellular and extracellular Mycobacterium tuberculosis organisms.

Resistance

Resistance to isoniazid occurs because of mutations in the katG, inhA, kasA and ahpC genes. Resistance in M. tuberculosis develops rapidly when isoniazid monotherapy is administered.

Susceptibility Testing

For specific information regarding susceptibility test criteria and associated test methods and quality control standards recognized by FDA for this drug, please see: www.fda.gov/STIC.

---

### Pyridoxine-dependent epilepsy: current perspectives and questions for future research [^111cNAYf]. Annals of the Child Neurology Society (2023). Medium credibility.

Pyridoxine-Dependent Epilepsy (PDE): Essential Clinical Features and Historical Aspects

First reported by Hunt and colleagues in 1954, PDE is frequently described as the prototypical metabolic epileptic encephalopathy that is unresponsive to antiseizure drugs, but which is generally successfully treated with a vitamin or another cofactor. These patients commonly present with medication-resistant neonatal seizures that may lead to status epilepticus and that come under control only with the addition of pharmacologic doses of pyridoxine (vitamin B 6) to their treatment regimen. – Concomitant improvement in the electroencephalogram (EEG) may occur as well, particularly if the patient is experiencing ongoing clinical seizures and EEG monitoring is conducted at the time of pyridoxine administration (Figure 1). The long-term treatment of these patients requires daily supplementation of large (i.e. pharmacologic, not physiologic) doses of pyridoxine. – Hence, these individuals are dependent on the vitamin; they are not deficient. Indeed, clinical pyridoxine deficiency is rare, with an incidence of 0.23 cases/100 000 person-year in US military personal; significant deficiency is associated with irritability, abdominal pain, insomnia, weakness, and difficulty with ambulation. In childhood, the most often cited example was iatrogenic pyridoxine deficiency secondary to an error in the manufacturing of infant formula, which led to an epileptic encephalopathy quite similar to the neonatal presentation of PDE. Importantly, a pyridoxine deficiency may be induced by treatment with isoniazid, and pyridoxine is the antidote for isoniazid overdose.